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Abstract
Transcriptome, deﬁned by the collection of all RNA molecules in a cell, acts as a central
bridge that transfers genetic information into molecular functions. Transcriptome regulates
the biological characteristics in all living organisms, thus it is one of the most important
research subjects in biology. RNAs are transcribed at different levels tightly controlled by
cellular conditions. This produces great diversity in cellular transcriptome dynamics,
introducing a lot of complexity to the transcriptomic research. Though tremendous
challenges exist, the study of transcriptome dynamics is essential to the understanding of
the complex systems within the cells and cellular behavior.
The dynamics of transcriptome can be investigated by high-throughput technologies, such
as microarrays and RNA-sequencing. The large amounts of data introduces challenges
to data management, analysis and interpretation. To generate biologically testable and
conclusive results, efﬁcient computational methods are urgently needed.
This thesis includes theoretical and methodological research. The theoretical part of the
research comprehensively studies the characteristics of gene expression, the splicing of
ancient and novel exons during the evolution by comparative analysis on transcriptomic
data of nine tissues from ﬁve species. The methodological research includes new methods
developed to solve the research questions related to the study of transcriptomic dynamics in
evolution and cancer. The main methods developed in this thesis are 1) exon age classiﬁer,
which is able to classify exons according to their evolutionary time, providing the basis for
the theoretical study in this thesis; 2) MEAP, a new exon array preprocessing method for
expression quantiﬁcation at multi-levels; 3) PSFinder, a new approach to identify patient
prognostic subgroups from treatment naive tumor samples based on their transcriptomic
proﬁles and associated clinical survival times.
The theoretical part gives a comprehensive view on the mechanisms of dynamic changes
during the evolution of the transcriptome, which provides a solid theoretical basis to
the methodological part. The application of MEAP and PSFinder to high-grade serous
ovarian cancer revealed a small set of isoform markers with distinct expression proﬁles for
patient prognosis stratiﬁcation. In combination with experimental validation, the results
demonstrate the applicability of these methods in the quantiﬁcation and stratiﬁcation of
tumor transcriptome dynamics, which provides new insights to the clinical diagnosis and
precision medicine for human cancers.
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摘要
转录组是细胞内所有RNA分子的集合，它将细胞内遗传信息编译为具体的功能性
分子。转录组调节了生物体内的各项生物学特性，是生物学中的重要研究对象之
一。在细胞各分子机制的严密调节控制下，RNA被转录为不同的水平。这产生了
细胞转录动态中的多样性,从而给转录组学的研究带来许多复杂性。因此转录组动
态的研究对了解细胞中的复杂系统及细胞行为极为重要，但也意味着转录组研究
的难度较高。
转录组的动态可以通过高通量技术，例如表达芯片及RNA测序来研究。大量的数
据给数据管理，分析及解释带来了挑战。有效的计算分析方法，是生成生物学上
可检测和确定性结果的关键。
本文包含了理论和方法的研究。该研究的理论部分对来自五种物种九种组织的转
录组数据进行比较分析，综合研究了在进化过程中基因表达及新老外显子的剪切
特性。该论文的方法学研究包括了为了解决进化及癌症中转录组动态研究的相关
问题而开发的新算法。本文中开发的主要方法有: 1)外显子分类器，它能够根据
外显子的进化时间对外显子进行分类。外显子的分类为该论文的理论研究提供了
基础。2) MEAP，一个外显子芯片预处理的新算法。该方法可以对表达进行不同
层面的定量。3) PSFinder，一种基于给药前转录组表达谱及给药后相关的临床存
活时间对病人预后进行亚组分类的新的方法。
理论部分着重分析了转录组进化过程中动态变化的机制，它对方法学的研究提供
了坚实的理论基础。MEAP和PSFinder在高级别浆液性卵巢癌中的应用，发现了一
小组转录物标记带有不同的表达谱，可以用来对病人的预后进行分类。与实验验
证相结合，结果证明了这些方法在定量及癌症转录组动态分类中的适用性。新方
法的开发为人类癌症临床诊断及精准医学提供了新的见解。
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1 Introduction
All living organisms originate from a single cell, a complex system with a myriad of
molecules and functional units co-operating with each other. Transcriptome, deﬁned by
the collection of all RNA molecules in a cell, exhibits great diversity tightly controlled by
cellular conditions and has been considered as a central component in a cell that transfers
genetic information into molecular functions. Although deciphering the underlying
mechanisms of the complex molecular world requires comprehensive study using high-
throughput data at multiple levels, such as genetic, epigenetic, transcriptomic and proteomic
levels [1, 2, 3], the transcriptome is the main focus of this thesis.
Since microarray technology was ﬁrst introduced [4], the high-throughput technologies
along with modern technologies have made great advances in the past ten years. This is
the era of big data [5]. Massive amounts of molecular data are available at the moment,
such as the data made from the 1000 Genomes Project [6] and the Cancer Genome Atlas
(TCGA) consortiums [3]. These have introduced challenges to data management, analysis
and interpretation. The big data has promoted the development of computer science with
an increasing number of computational methods developed over the years. However, the
translation from computational results to biological applications is still a long way to go
due to the challenges in terms of data and biological world.
The dynamics of transcriptome is a general phenomenon that is embodied in many aspects
of biology. A good model to study the mechanism of such dynamic changes is via evolution,
a process with changes occurring over the time [7]. The study of evolution requires
comparative analysis by using large-scale molecular data generated from high-throughput
technologies. Although in the past few years many efforts have been made to identify
the regular patterns of the dynamic changes during the evolution of the transcriptome,
the studies have focused on speciﬁc areas and have limitations in terms of data and
technologies [8, 9]. With the latest deep sequencing technology, a better picture on the
overall mechanisms of transcriptome dynamics can be drawn in a more comprehensive
way.
Cancer is one of the severe diseases that affects the human health worldwide. Although
several cancers, such as testicular cancer and thyroid cancer, exhibit high cure rates at
the moment [10, 11], most cancers develop treatment resistance resulting in therapeutic
failure [12, 13]. Cancer research is multidisciplinary and more complex than other ﬁelds
of research, which requires combinatorial efforts from biologists, biochemists, clinicians,
mathematicians, bioinformaticians and computer scientists among others. The emergence
of high-throughput molecular data, such as TCGA, has accelerated the pace of cancer
research. Huge diversity in cancer molecular proﬁles, especially the transcriptomic proﬁles,
make it clear that cancer is a heterogeneous disease that requires the reformation of current
therapeutic strategies [3, 1, 14, 2]. However, it is not easy to translate the biological ﬁndings
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from research to clinical patient treatments. In addition to the high-throughput technologies,
translational research requires more efﬁcient computational methods incorporated with
molecular biology to accurately quantify and stratify the molecular diversities within
patients, which can help to understand the molecular mechanisms that drive cancer
progression and to identify crucial molecules for targeted therapy.
This thesis presents a comprehensive study of transcriptome dynamics by data analysis
on high-throughput data, which includes theoretical and methodological part of work.
The theoretical research and methodological research complement each other. The
theoretical research aims to understand the characteristics and the molecular mechanisms
of transcriptome dynamics, which provides the foundation for the methodological research
with the goal of developing new computational solutions and applying them to cancer
research. Computational approaches developed from the methodological research can be
used in the theoretical study to explore the underlying biological mechanisms. Results
from the application of these methods to cancer research described in this thesis provide
new insights to the clinical diagnosis and precision medicine for human cancers.
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Figure 1: The ﬂow of genetic information from DNA to RNA to protein by transcription
and translation. The structure of eukaryotic protein-coding gene, mRNA and protein
together with the process of transcription, post-transcriptional modiﬁcation, translation
and post-translational modiﬁcation are illustrated.
2 Transcriptome
The classical central dogma of molecular biology describes the ﬂow of genetic information
from DNA to RNA to protein. The step where the genetic information is passed from DNA
to RNA is called transcription, whereas the step in which the genetic information is passed
from RNA to protein is called translation. RNA, a bridge connecting gene to protein,
carries out a wide range of functions, such as regulating gene expression and translating
genetic information into molecular functions in a cell [15, 16].
Gene, a segment of DNA sequence, harbours genetic information that can be inherited
by the offspring. The classical structure of a eukaryotic protein-coding gene consists of
regulatory sequences (enhancer/silencer, promoter, 5’UTR) at 5’ end, as well as open
reading frame (ORF) and regulatory sequences (3’UTR, enhancer/silencer) at the 3’ end
as shown in Figure 1. The ORF region of a gene contains series of exons (which
are transcribed into mature mRNA and translated into protein) isolated by noncoding
interspersed sequences called introns (which are removed from the mature mRNA). During
the transcription, the antisense strand of a gene acts as a template and synthesizes a
single-stranded pre-mRNA by base complementarity, which is composed of 5’UTR, ORF
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and 3’UTR of the gene. The pre-mRNA is protected from degradation by adding a 7-
methylguanosine cap to its 5’ end and a poly-A tail to its 3’ end. By splicing, in which
intronic sequences are removed and exons are spliced together, a mature mRNA is formed,
which is then used as a template for synthesizing a protein sequence with amino acids.
High-throughput technologies brought the concept of "-ome", which refers to the complete
set of objects, such as genome (all DNA in a cell), transcriptome (all RNA molecules in a
cell) and proteome (all proteins in a cell). The genome of an organism originates from a
single zygote and is ﬁxed in almost every cell. However, the transcriptome and proteome
exhibits huge diversity within the cells as not all the genes or proteins are expressed at the
same time, and their expression is tightly controlled by conditions inside and outside of the
cell. Though tremendous challenges exist, the study of transcriptome dynamics is essential
in order to understand the complex systems within the cells and the cellular behaviors.
2.1 Types of RNAs
Transcriptome comprises all sets of RNAs in a cell, including protein-coding RNAs
(pcRNAs) and non-coding RNAs (ncRNAs). Protein-coding RNAs are messenger RNAs
(mRNAs) that are transcribed in the nucleus, exported into cytoplasm and then translated
into functional proteins. Mammalian genomes encode ∼20,000 protein-coding genes,
which only accounts for 1.5-2% of the genomic sequences [17, 18, 19, 20]. Up to now,
most of the transcriptomic studies have been concentrating on pcRNAs as they are assumed
to be the main functional contributors in a cell [21, 22]. Although this type of RNAs has
been widely studied, the translation from genetic information into biological function is
still challenging due to the complexity arising from numerous isoforms produced by the
genes [23, 22, 24].
Unlike pcRNAs that produce proteins, ncRNAs are functional RNAs that do not encode
proteins. Interestingly, recent studies have uncovered that pcRNAs only account for a
small portion of the transcriptome whereas the majority of the transcriptome are occupied
by ncRNAs [25, 26, 19, 20], which can be divided into short (<200 nt) and long (>200 nt)
ncRNA classes based on the sequence length [27, 28]. Short ncRNAs includes microRNAs
(miRNAs) (22-23 nts), piwi-interacting RNAs (piRNAs) (26-31 nts), small nuclear RNAs
(snRNA) (∼150 nts), transfer RNAs (tRNAs) (76-90 nts) and most of small nucleolar
RNAs (snoRNAs) (60-300 nts). These short ncRNAs are involved in core functions
of the cell. For example, miRNAs regulate gene expression via mRNA degradation or
translational repression [29]; snRNAs are involved in RNA splicing and play roles in the
regulation of RNA biogenesis [30]; tRNAs participate in mRNA translation [31] and
snoRNAs play roles in chemical modiﬁcations of other RNAs such as ribosomal RNAs
(rRNAs), tRNAs and snRNAs [32].
Long ncRNAs received much attention in recent years as they have been found to play
essential roles in regulating epigenetic modiﬁcation, transcription and translation [33, 34].
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Numerous studies have indicated their roles in the development of human diseases, such
as cancer [20, 19, 35, 36, 37]. There are several classes of long ncRNAs based on the
transcript length, including long ncRNAs (lncRNAs), lincRNAs (long intergenic non-
coding RNAs), vlincRNAs (very long intergenic non-coding RNAs), macroRNA and
PALR (promoter-associated long RNAs) [25], which account for a large proportion of the
ncRNAs [34, 38].
2.2 Transcriptional regulation
The regulation of gene transcription is collaboratively controlled by multiple components,
including chromatin structure, various types of factors (transcription factors, co-activators,
etc.) and RNA polymerases. In eukaryotes, there are three types of RNA polymerases,
including RNA polymerase I (Pol I) for the transcription of rRNAs, excluding 5S rRNA;
RNA polymerase II (Pol II) for mRNAs and most miRNAs and snRNAs; and RNA
polymerase III (Pol III) for tRNAs, 5S rRNA and other small RNAs [39, 40, 41]. The
transcription of pre-mRNA can be divided into three main steps, which are transcription
initiation, elongation and termination.
The transcription is initiated by assembling a transcription initiation complex at the
promoter region and synthesizing the ﬁrst two nucleotides with phosphodiester bond [42].
The main elements in the complex are the DNA template, Pol II and general transcription
factors, such as TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH [43]. In addition, many
classes of proteins are also involved in the initiation step. For example, activator proteins
that bind to the distal enhancer sequences communicate with the initiation complex via
mediator proteins to increase the transcription activity of the target gene [44]. Epigenetic
modiﬁcations of DNA and changes in chromatin structure can directly affect the formation
of the initiation complex by restricting the access of transcription factors and Pol II to the
DNA template [45]. The transcriptional initiation transits into elongation phase when a
nascent RNA chain with at least eight nucleotides is produced [46].
When transcription enters the elongation stage, all the general transcription factors are
dissociated from the Pol II and stay at the promoter region to initiate another Pol II.
An elongation complex with DNA template, Pol II and nascent RNA is formed and it
moves along the DNA template to synthesize the complete pre-mRNA chain from 5’ to 3’
direction by adding new nucleotides to the 3’ end of the chain. Many protein factors are
involved in this step to overcome the obstacles during the elongation, such as TFIIF, TFIIS
[47] and SPT6 [48].
When the nascent RNA and the RNA polymerase are released from the DNA template,
transcription enters the termination phase. The nascent pre-mRNA is cleaved in co-
operation with a protein complex comprising the cleavage and polyadenylation speciﬁcity
factor (CPSF) which binds to the polyadenylation signal (PAS), the cleavage stimulation
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factor (CstF) which binds to the downstream GU-rich region and interacts with the CPSF,
and cleavage factors, such as CFI and CFII [49, 50]. The cleavage occurs at 18-30 nt
downstream of PAS, and the nascent RNA continuously produced by Pol II is digested by
a 5’-exonuclease, such as XRN2 in human. A poly-A tail is added to the 3’ end of the
pre-mRNA by poly-A polymerase enzyme in the termination complex [50].
2.3 Alternative splicing
Alternative splicing is catalyzed by the spliceosome, a complex comprising ﬁve small
nuclear ribonucleoproteins (snRNPs), which function in collaboration with a large number
of trans-acting factors. The spliceosome recognises and binds to intronic motifs (5’ splice
donor sequence, 3’ splice acceptor sequence and the branch point sequence upstream of
the 3’ splice site) in cooperation with several splicing factors, such as SF1 and U2AF [51].
There are two classes of spliceosomes, of which the major spliceosome is composed of U1,
U2, U4/U6 and U5, whereas the minor spliceosome consists of U11, U12, U4atac/U6atac
and U5. A set of trans-acting factors recognizes the splicing enhancer (ESE, ISE) and
silencer (ESS, ISS) elements within exonic and intronic sequences and interacts with
the spliceosome to regulate the inclusion and exclusion of exons for RNA maturation.
Alterations in regulatory factors and mutations in splicing machinery may result in aberrant
splicing which cause phenotypic changes [52].
Alternative splicing is a key process to produce different transcript isoforms for a gene
through selective inclusion/exclusion of speciﬁc exons. It occurs frequently in multi-exonic
genes [53]. In human, about 95% genes undergo alternative splicing producing three
isoforms per gene on average [53, 54]. It is the main source behind the diversity of
transcriptome and proteome, and provides functional complexity. Alternative splicing
impacts various cellular and developmental processes, including cell growth, apoptosis,
differentiation, sex determination, axon guidance and others [55, 56, 51]. Mis-regulation
of alternative splicing has been linked to many human diseases, such as cancer [57],
neurodegeneration [58], disruption of cholesterol homeostasis [59] and blood coagulation
[60], systemic sclerosis [61] and cardiovascular disease [62]. Numerous studies have
shown the roles of alternative splicing during tumorigenesis and tumor progression.
Aberrant splicing was found in genes involved in various cancer related processes, such as
proliferation, apoptosis, differentiation, invasion, metastasis, angiogenesis and signaling in
cancer associated pathways [63].
Alternative splicing can be divided into seven main categories (Figure 2), which are
cassette exon, alternative 5’ splice site, alternative 3’ splice site, intron retention, mutually
exclusive exons, alternative promoter and alternative polyadenylation [64]. Cassette exon
(Figure 2A), also called exon skipping, is the most frequent event (∼40%) of alternative
splicing, where one or multiple exons are removed from the transcript together with the
ﬂanking intronic sequences [65]. An example of cassette exon can be found in BRAF,
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A. Cassette exon 
B. Alternative 5’ splice site 
C. Alternative 3’ splice site 
D. Intron retention 
E. Mutually exclusive exons 
F. Alternative promoter 
G. Alternative polyadenylation 
Figure 2: The classes of alternative splicing. Seven different classes of splicing events
(A-G) are illustrated with the structure of exon and intron in gene shown on the left and
the spliced isoforms shown on the right.
which is a proto-oncogene with a lethal mutation V600E commonly found in patients with
malignant melanomas [66]. BRAF inhibitors are non-functional in patients expressing
a BRAF mutant isoform with the skipping of exon 4-8 which encode the RAS-binding
domain, but are sensitive in patients without the exon skipping [67]. Alternative 5’ and
3’ splice sites (Figure 2B-C), accounting for 8% and 18% of alternative splicing cases,
respectively [65], are the classes where one of the multiple splice sites at one end (5’ end
or 3’ end) of an exon is selected for splicing. A well known example of alternative 5’ splice
site can be found in BCL2L1, which encodes the BCL-X protein. It produces two isoforms
with opposite functions, of which the shorter isoform (BCL-XS) promotes apoptosis and
the longer form (BCL-XL) inhibits apoptosis [68]. Intron retention (Figure 2D) is the third
most frequent alternative splicing class (∼3%) where an intron is retained in the mature
mRNA [65]. This often introduces a premature stop codon to the transcripts, which alters
the protein structure or triggers the nonsense-mediated mRNA decay (NMD) pathway
[69, 70]. Transcripts with retained intron, for example in STAT2 [71] and ABCD1 [72],
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have been associated with diseases. Mutually exclusive exons (Figure 2E) is a rare class
where one of two exons is retained in the mature mRNA but never both. Splicing variants
from the same gene containing one of these exons can produce proteins with diverse
functions. For example PKM, a gene encoding pyruvate kinase involved in glycolysis, can
produce two isoforms including mutually exclusive exon 9 or 10. The isoform including
exon 9 is expressed in differentiated tissues, whereas the isoform including exon 10 is
expressed in tumors and associated with tumor growth [73]. Alternative promoter usage
and alternative polyadenylation (Figure 2F-G) are two frequent cases of alternative splicing.
Recent studies indicated that there are about ∼30-50% [74] and ∼70-75% [75] of genes
possess alternative promoter and polyadenylation sites in human. The alternative usage of
promoter and polyadenylation sites is regulated by the transcription and polyadenylation
machinery during transcription initiation and termination. Aberrant use of these alternative
sites has been found to be associated with many diseases. For example, LEF1 uses its
ﬁrst promoter for producing a full length isoform so as to interact with the Wnt signaling
pathway in colon cancer [76].
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3 Expression measurement technologies
Expression measurement is central to the study of transcriptome and the whole research
ﬁeld of life science. Measuring the expression level of genes in a cell, tissue or organism
provides valuable information to understand the active components and the underlying
biological mechanisms. For example, the expression of cancer associated genes, such as
oncogenes and/or tumor suppressor genes, predicts the cancer susceptibility for individuals
[77]. Several biomarker panels are available for diagnostic test, such as MammaPrint [78,
79] and Oncotype DX [80] in breast cancer. There are various measurement technologies,
which can be categorized into two main classes: hybridization-based and sequence-based
approaches.
3.1 Hybridization-based approaches
Hybridization-based approaches use probes, nucleic acid sequences complementary to
all or part of the transcripts of interest, to measure the expression of genes by sequence
complementarity. There are several hybridization-based approaches including northern
blotting, quantitative reverse transcription PCR and microarrays.
3.1.1 Northern blotting
The procedure of northern blotting follows these steps: 1) extracting RNAs from samples of
interest, 2) separating RNA molecules based on their size by electrophoresis, 3) transferring
the separated RNAs onto a membrane and ﬁxing the RNAs with UV light or heat, 4)
hybridizing labeled probes with target RNA on the membrane, and 5) visualizing the
labeled RNAs by detectors [81].
Northern blotting has several advantages when studying one or a small number of genes.
For example, it is able to measure and quantify the gene expression in different samples
at the same time, allowing direct comparison of the expression levels between samples
in different conditions. As it separates RNAs based on the size, splicing variants with
signiﬁcant size differences can be detected with a good resolution. In addition, membranes
can be stored and re-used after several years, which is cost-effective. However, it is
not recommended to use northern blotting when studying the gene expression in a high-
throughput manner. Several disadvantages of northern blotting have been discussed, such
as RNA degradation, the toxicity of the reagents and low sensitivity. [82].
3.1.2 Quantitative reverse transcription-PCR
Quantitative reverse transcription PCR (qRT-PCR) is a hybridization- and ampliﬁcation-
based approach for gene expression measurement. It combines two techniques, reverse
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transcription polymerase chain reaction (RT-PCR) and real-time polymerase chain reaction
(qPCR), to quantify the expression at RNA level. Similar to RT-PCR, a qualitative gene
expression measurement, qRT-PCR starts with reverse transcription from single-stranded
RNA into double-stranded cDNA by using a set of primers complementary to the ends
of target region and is followed by sequence ampliﬁcation in exponential mode. It uses
special probes with ﬂuorescent dyes that emit signals from each ampliﬁcation cycle. The
signal intensity accumulates following each cycle, and is captured by detector. Eventually,
at certain cycle, the signal intensity becomes strong enough to reﬂect on the detector,
this cycle number will be recorded for expression quantiﬁcation. Therefore, larger cycle
number represents lower amount of cDNAs of certain gene.
qRT-PCR is a widely used method for expression quantiﬁcation. It detects more quantitative
results than other methods, such as RT-PCR. However, it is a low-throughput method and
only a small number of genes can be analyzed at the same time. Thus, it is a suitable
method when studying a limited set of genes of interest.
3.1.3 Expression microarrays
Expression microarrays, a high-throughput technology, are able to measure the expression
of most genes simultaneously. On an expression microarray, there is a large collection of
spots attached with numerous nucleic acid sequences, called probes, which are designed
to hybridize with their target transcripts for estimating their abundance in the sample. In
general, the expression microarray measures the expression following the steps below: 1)
extracting RNA from samples of interest, 2) reverse transcribing RNAs into cDNAs, 3)
labeling cDNAs with ﬂuorescent dyes, 4) hybridizing labeled cDNAs with complementary
probes on the array, 5) washing away unbound cDNAs, 6) scanning the array to measure the
ﬂuorescence intensity at each spot on the array, and 7) data processing for gene expression
quantiﬁcation [83].
There are different types of expression microarrays. According to the manufacturing
technique for the probes, they can be classiﬁed into spotted arrays and in-situ synthesized
microarrays [84], whereas according to the channel numbers accepted on the array, there
are one-channel and two-channel microarrays [85].
In spotted microarrays, the probes can be cDNAs or oligonucleotides. They are ﬁrst
synthesized then ampliﬁed and spotted to their designated locations on the slides by a
robotic machine. A spotted array often contains tens of thousands of spots that represent
different genes. Each spot contains numerous copies of a probe sequence complementary
to a segment of a target gene, and the spots are arrayed on the slides in the same order
from slide to slide. The spotted arrays are easier to be customized for genes of interest,
which is cost-effective.
In in-situ synthesized microarrays, the probes are short oligonucleotide sequences which
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match to the fragments of known genes and are synthesized on the slides directly instead of
spotting. There are several commercialized platforms available for this type of microarrays,
including two widely used array platforms, Affymetrix and Agilent. Affymetrix arrays
build the 25-mer probes by photolithographic synthesis [86], in which a set of photolitho-
graphic masks with transparent windows are used to allow one type of nucleotides to be
synthesized at the designated locations in parallel at a time. There are three types of arrays
available in Affymetrix, which are 3’-IVT arrays (multiple probesets designed against the
3’ end of each gene with 11 pairs of perfect match and mismatch probes per probeset),
GeneChip exon arrays (perfect match probes designed against the full length of a gene
region with 4 probes per exon and ∼ 40 probes per gene) and GeneChip gene arrays
(perfect match probes designed against the full transcribed regions for each gene with a
median of 26 probes per gene). 3’-IVT arrays use mismatch probes whereas GeneChip
arrays use a special pool of background probes to detect the background signals. In
contrast to Affymetrix, Agilent arrays use inkjet printing technique to print the 60-mer
oligonucleotide sequences base by base on the slides [87]. They contain a much smaller
number of probes than Affymetrix, as most of the genes are represented by a single longer
probe with increased speciﬁcity to their target binding.
In two-channel microarrays, two samples labeled with two different ﬂuorescent dyes (Cy3
and Cy5) are mixed together and hybridized onto a single array. The two ﬂuorescent dyes
emit different wavelengths that can be visualized as different colors under a scanner. Two
samples can be directly compared on a single array and the relative expression level of
each gene is then measured by the ratio of two intensity values from the same gene spots.
Two-channel microarrays include spotted arrays and Agilent arrays. For one-channel
microarrays, only one sample can be hybridized onto a single array, which generates
absolute expression levels for each gene. When comparing gene expression between two
samples, two separate single-channel arrays are needed. One-channel microarrays include
Affymetrix, Agilent and Nimblegen arrays.
3.2 Sequence-based approaches
Sequence-based approaches have many advantages over the hybridization-based ap-
proaches for gene expression measurements. Different from hybridization-based ap-
proaches which measure the expression levels by ﬂuorescence intensities, sequence-based
approaches measure the transcript abundance based on the sequence counts, which enable
the absolute expression quantiﬁcation. In addition, the high-throughput sequence-based
approaches allow the study of the whole transcriptome, and the sequenced data do not need
to depend on existing annotations, which makes the discovery of novel events possible.
There are several sequence-based approaches, such as expressed sequence tag (EST), serial
analysis of gene expression (SAGE) and next generation RNA sequencing.
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3.2.1 Expressed sequence tag sequencing
An expressed sequence tag (EST) is a single-pass sequence read from one end of a cDNA
clone with the average length of 400-600 bases. In EST sequencing, all the mRNAs in
a sample are extracted based on poly-A tails, reversely transcribed into double-stranded
cDNAs and inserted into cloning vectors to build a cDNA library. The ESTs are then
sequenced from one or both ends of the inserts of the random clones from the cDNA
library. As many EST sequences may come from same transcripts, the ESTs are often
clustered into unigenes after removing contaminating sequences, such as low quality base
calls, Escherichia coli, short sequences (<100 bp), cloning vectors and artiﬁcial primers or
linkers used in the sequencing [88].
EST sequencing generates large valuable resources for the transcriptome study, which
provide a high-throughput means for gene discovery, gene sequence identiﬁcation and
expression level measurement [89, 90]. However, several limitations exist due to 1)
insensitivity to the low expressed genes, 2) uneven distribution along the full-length
transcript, and 3) difﬁculty in the validation of unigenes when no reference genome
available [88].
3.2.2 Serial analysis of gene expression
Serial analysis of gene expression (SAGE) is a powerful sequence-based approach for
expression quantiﬁcation that allows the analysis of thousands of transcripts together. By
assuming that short sequences with the length of 9-10 bases can uniquely represent a
transcript, SAGE quantiﬁes the gene expression by measuring the occurrence of small
tags [91]. In SAGE, mRNAs with poly-A tails are extracted from a sample and reverse
transcribed into double-stranded cDNAs. cDNAs are cleaved by a restriction endonuclease
called anchoring enzyme (AE), and the 3’ end of the cleaved cDNAs are isolated by
binding to the beads. The cleaved cDNAs are divided into half and ligated with two linker
sequences (A and B) to the anchoring restriction sites (AE sites), which direct the tagging
enzyme to cleave the cDNA at a deﬁned short distance downstream of the restriction sites.
Two cleaved cDNA pieces with the length of ∼9-10 base pairs are then ligated together
into ditag ﬂanked by AE and TE sites at both ends. The ditags with restriction sites are
further cleaved with the anchoring enzyme and concatenated with other ditags together.
The expression of genes is then quantiﬁed by occurrence of each tag speciﬁc to a transcript.
There are several disadvantages of the SAGE approach [92]. For example, it requires
large amount of RNA in the samples, which makes it difﬁcult to use when RNA is limited.
The tags are short and may increase errors when mapping to the reference. Moreover,
construction of the tag library is relative difﬁcult and expensive, which may not be ideal
for the study of multiple samples at the same time.
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Figure 3: Key steps in RNA-seq (Illumina) library preparation and sequencing. (A) Adaptor
ligation. (B) Bridge ampliﬁcation. (C) Sequencing by synthesis.
3.2.3 RNA-sequencing
RNA-sequencing (RNA-seq) is the most popular high-throughput technology for the study
of gene expression as well as alternative splicing, gene fusion, small RNAs and post-
transcriptional single nucleotide variations (SNVs) at the moment [93, 94, 95, 96]. It
allows the study of whole transcriptome at a single-base resolution with high accuracy and
relatively low cost, and is able to analyze multiple samples at the same time. RNA-seq
produces a large amount of sequencing data with increased read coverage along the full-
length transcripts, which facilitates the discovery and annotation of complete transcripts
and does not need to be limited to existing knowledge [97]. An RNA-seq workﬂow
includes the following steps: RNA sample preparation, library construction, sequencing
and data analysis.
As RNA-seq is designed to study the transcriptome, RNAs ﬁrst need to be extracted
from the cells. There are two extraction protocols, poly-A based and total RNA based
extractions. The poly-A based protocol aims to extract the mature mRNAs by poly-A
tails, which excludes non-polyadenylated RNAs from the study. In contrast, the total RNA
based protocol aims to extract all the RNAs except rRNAs, which account for >80% of
RNAs in the cells [98]. The extracted RNAs are further puriﬁed by size-selection and
followed by fragmentation. The size-selection can enrich target RNAs under certain size
range according to the research goals, such as the study of small RNAs, whereas RNA
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fragmentation randomly cuts the extracted RNA sequences into small pieces to improve
the coverage along the full-length transcripts.
In library preparation, the fragmented RNAs are converted into double-stranded cDNA
and platform-dependent adaptors are added to both ends to enable the ampliﬁcation and
sequence elongation reactions during the sequencing step. The library construction varies
from protocol to protocol. In Illumina, there are several types of adaptors: ampliﬁcation
adaptors, priming adaptors and optional barcode/index elements, shown in Figure 3A.
Ampliﬁcation adaptors are attached to the 5’ and 3’ ends of the fragments with the role
for fragment ampliﬁcation during sequencing. The priming adaptors are adjacent to the
inserted RNA fragment sequence, and are used to initiate the sequencing reactions by
hybridizing with complementary primers for elongation. Single-end sequencing requires
only one priming adaptor attached to one end, whereas pair-end sequencing requires two
priming adaptors inserted to the both sides of the fragments. The optional barcode/index
elements are added to the fragments for labeling RNA fragments from different samples.
For instance, in the Illumina TruSeq protocol, the barcode/index sequences with the length
of 5-7 bp are inserted between ampliﬁcation and priming adaptors at the 3’ end.
The sequencing step is platform-speciﬁc. There are several sequencing platforms available,
including Illumina, Ion Torrent from Life Technologies, 454 pyrosequencing from Roche
and PacBio. Although each platform has its own advantage over the others, Illumina
is the most popular and leading sequencing technique at the moment in terms of its
ability to generate large amounts of data with low error rates and costs, and the ﬂexibility
in the choice of platform size and sequencing strategies such as single-end or pair-end
reads [99, 100]. Illumina uses the bridge ampliﬁcation approach on a solid-phase surface
by repeatedly synthesizing double-stranded bridges from single-stranded templates and
denaturing from double-stranded bridges into single-stranded sequences with the help
of ampliﬁcation adaptors. The sequences are then read from 3’ end to 5’ end along the
templates by iteratively adding free deoxyribonucleoside triphosphates (dNTPs) to the
synthesized chain complementary to the template sequences starting from the priming
sites. An illustration on the bridge ampliﬁcation and sequencing-by-synthesis for pair-end
reads is shown in Figure 3B-C. The end output of the sequencing step is raw fastq ﬁles
containing millions of read sequences, which are then input into analysis pipeline for
quality control, read mapping and expression quantiﬁcation.
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4 Evolution of transcriptome
Evolution refers to a process where changes are developed over time to produce diverse
descendant species from a common ancestor [7]. Darwin’s theory of evolution pointed
out that natural selection is a key mechanism that drives the evolution of all organisms
[7]. Random mutations can occur in individuals and be passed to their offsprings. Natural
selection is a selection of ﬁttest, in which individual organisms with mutations beneﬁcial
to the survival are preserved, survive long and produce offspring, whereas individuals with
inferior mutations gradually die out and are eliminated from their population.
4.1 Phylogenetic inference
Phylogenetic inference aims to speculate the evolutionary history of a set of entities, such
as species and genes, based on a sequence of characters from molecular, morphological,
behavioral or physiological data. A branching diagram, called a phylogenetic tree,
represents the inferred phylogenetic relationships among the entities/taxa. This section
provides a brief introduction on the phylogenetic tree and the methods for the tree
construction.
4.1.1 Phylogenetic tree
A phylogenetic tree is composed of nodes and edges. It can be rooted or unrooted. A
rooted tree is a direct tree which reﬂects the evolutional relationships of all the entities at
the leaf nodes with a unique vertex designated as their common ancestor (Figure 4A). An
unrooted tree (Figure 4B) shows the relationships among the entities without knowledge
of the ancestry.
Phylogenetic trees can be represented in different ways, in the form of phylogram or
cladogram [101]. A phylogram tree (Figure 4C) has branches with different lengths
representing the number of evolutionary changes, often called substitutions. However, in
the cladogram (Figure 4D), all the branches have equal lengths and thus a cladogram tree
cannot visualize the corresponding evolutionary time for each entity.
4.1.2 Methods for phylogenetic tree construction
Several methods are available for the tree construction. These can be summarized into
two main categories, 1) phenetics and 2) cladistics [102]. A phenetic approach constructs
a phylogenetic tree based on a distance/similarity matrix, in which the two most similar
or least distant entities are ﬁrst grouped together. This includes several popular methods,
such as UPGMA [103] and neighbor joining (NJ) [104]. A cladistic method generates all
possible tree topologies based on shared derived characters or traits, called synapomorphies,
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Figure 4: The shape of phylogenetic trees. (A) Rooted tree. (B) Unrooted tree. (C)
Phylogram tree. (D) Cladogram tree.
and selects the tree that best optimizes the hypothesis. The typical examples of the cladistic
method includes maximum parsimony and maximum likelihood [105]. In maximum
parsimony, all the trees are scored by the number of evolutionary changes and the tree with
the lowest number of changes is selected as the ﬁnal tree. Instead of scoring by the number
of changes, the maximum likelihood method calculates a conditional probability for each
tree and selects the tree with the highest probability as the ﬁnal tree.
4.2 The evolution dynamics of transcriptome
High-throughput technologies have generated valuable resources for comparative studies of
transcriptome expression proﬁles and regulatory mechanisms across divergent species and
tissues/organs. Although microarray-based analyses have revealed the evolution of gene
expression across different mammalian lineages, the use of microarray data is restricted as
the probes were designed for only a limited set of annotated genes of a species. RNA-seq
data can overcome such issues and is able to achieve the comparative studies at the whole
transcriptome level including both annotated and unannotated transcripts even when the
genome of the species is unknown [106].
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4.2.1 The rate of transcriptome evolution
In the past few years, expression proﬁles from different parts of the transcriptome have
been studied by using the RNA-seq approach [22]. At the level of protein-coding genes,
conserved expression patterns were seen in the same organs across divergent species, which
indicates that the evolution of expression of protein-coding genes is strictly controlled by
the organ-speciﬁc functions [107]. At the level of alternative splicing, species-speciﬁc
expression patterns were observed from the comparisons of multiple species [108, 109,
110]. However, the regulatory mechanisms of the species-speciﬁc alternative splicing is
still poorly known.
Non-coding genes revealed both slow and fast evolutionary rates. For example, a group of
miRNAs were conservatively expressed across mammalian lineages, whereas lncRNAs
showed rapid evolution of their expression across multiple species [111, 112]. As there
are several issues that may introduce biases to the data and other types of non-coding
genes that have not yet been explored, more in-depth studies are required to clarify the
evolutionary roles of non-coding genes in organ development and speciation.
In addition, the rate of the transcriptome evolution varies among different organs/tissues
and lineages [22]. For example, a slow rate was found in the brain and neural tissues,
whereas a high rate of expression evolution was identiﬁed in the testis [113, 107], which
is in accordance with the frequent emergence of new genes during evolution in this tissue
[114]. The comparison between different mammalian lineages revealed faster expression
evolution in primates than in rodents, which could be explained by ineffective natural
selection that causes the accumulation of deleterious mutations in primates, therefore
inducing expression changes [22].
4.2.2 Factors contributing to the evolution of gene expression
Genetic variation and environmental changes are the two major sources that affect gene
expression [106]. Although it is still unclear to what extent they contribute to the inter-
species changes, several comparative studies have explored the connections from different
aspects. For example, from the comparison of genetic variation of the same cell type across
human, chimpanzee and macaque, hundreds of species-speciﬁc mutations occurring in non-
coding regulatory regions were identiﬁed to be associated with the evolutionary changes in
gene expression [115]; altered DNA promoter methylation was linked to the expression
differences in a subset of genes between humans and chimpanzees [116]; variations in
miRNAs expression and mutations in miRNAs and/or their target sites, were found to
contribute to the increased variation in gene expression during primate evolution [117];
comparison of transcription factor binding sites among multiple species on a genome-wide
scale revealed species-speciﬁc patterns, underlying the regulatory roles of transcription
factors in driving the evolution of transcriptome [118].
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4.3 The emergence of new genes and exons during evolution
The creation of new genes and exons has been considered as a driving force of the
evolutionary innovations in all the organisms. In recent years, several studies have revealed
the mechanisms that drive such events, which are summarized below.
4.3.1 The birth of new genes
Several molecular mechanisms have been linked to the emergence of new genes, including
DNA duplication, de novo creation, retrotransposon mediated creation, gene fusion or
ﬁssion, and transferring endogenous elements into the host genome.
DNA duplication and de novo creation are the two major sources of new genes [114, 119].
Genes can be duplicated in different ways, such as by duplicating the entire genome
with all genes or segments of a genome containing a large group of genes or individual
genes [114]. Duplication of protein-coding genes can produce some copies with original
functions of the ancestor genes and other copies for new genes with novel functional
properties [114, 120]. De novo gene creation, where new genes arise from non-genic
sequences, is a novel mechanism identiﬁed recently and is considered as a more prevalent
mechanism than DNA duplication [119]. In order to create new protein-coding genes
from non-functional genomic regions, the de novo mechanism requires that such DNA
regions are capable of active transcription and translation into non-deleterious proteins
[114]. In addition to the creation of protein-coding genes, DNA duplication and de novo
creation can both give rise to new non-coding genes, such as miRNA and lncRNA, which
may play roles in the regulation of transcriptome evolution [114].
Retrotransposon can contribute to the creation of new genes via two different mech-
anisms: retrotransposon-mediated transduction and gene retrotransposition [114]. In
retrotransposon-mediated transduction, a retrotransposon can carry a downstream ﬂanking
sequence and insert the sequence together with the upstream retrotransposon into new
genomic locations to form new gene structures. An example of such case is a new gene
family created by the transduction of the entire AMAC1L3 gene sequence mediated by
SVA, a retrotransposon family, during human evolution [121]. In contrast, new genes
can also arise from inserted DNA sequences via retrotransposition catalyzed by a reverse
transcriptase encoded by a retrotransposon. In Drosophila testis, many new retrogenes were
retrotransposed from the X chromosome to the autosomes, associated with X inactivation
during spermatogenesis [122]. In addition, retrotransposition has been considered as an
important mechanism driving new gene generation in primates and is a contributor to the
emergence of new species-speciﬁc phenotypes [123].
New genes can also be formed by gene fusion or gene ﬁssion [114, 124]. Gene fusion is
often associated with new functionality, in which entire or partial sequences from two or
more genes are fused together. A well known example is jingwei, which is a new functional
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chimeric gene formed from a yellow-emperor gene and an Adh retrosequence in their
common ancestor, identiﬁed in a group of African Drosophila species [125]. Gene ﬁssion,
in which a single gene is split into different segments, is a reversed mechanism to create
new genes. In the same Drosophila species, two new genes mkg-p and mkg-r3 were created
by such mechanism [124].
In addition, endogenous parasites, such as retroviruses and bacteria, can also introduce new
genes to the host genome. In Drosophila, a transmembrane protein GRP, which originated
from the errantivirus GAG gene, aquired a new function to interact with retroviral proteins
during infection [126]. A whole-genome sequencing study on Drosophila demonstrated a
potential mechanism to create new genes by transferring genes from prokaryote symbionts
to their host genome [127].
4.3.2 The birth of new exons
New exons were earlier reported to arise from tandem exon duplication [128, 129], a
process in which an exon is duplicated into subsequent exons inside a gene. Over the
past few years, several attempts have been made to discover the molecular mechanisms
behind the creation of new exons; of these, repetitive elements have appeared as the major
contributor to new exons [9, 130, 131].
Eukaryotic genomes contain a signiﬁcant fraction of repetitive sequences. For example,
over 50% of human genome and 20% of mouse genome are composed of repeated
sequences [132]. Repetitive sequences can be classiﬁed into two major categories: tandem
repeats and interspersed repeats. Tandem repeats are composed of sequences arrayed
adjacent to each other. Based on the location and the length of the repeat unit, they can
be classiﬁed into satellites, minisatellites and microsatellites. Interspersed repeats are
dispersed in the genome. These mainly contain transposable elements, such as DNA
transposons and retrotransposons.
Short interspersed elements (SINEs) are retrotransposons evolved independently after
the primate-rodent split. Primate-speciﬁc SINEs are called Alu elements whereas rodent-
speciﬁc SINEs are often called B1 elements [133, 134]. Exonization is a process in
which genes acquire new exons from non-coding intronic DNA sequences. Several studies
have revealed the great impact of Alu elements on the exonization in the human genome
[9, 130], according to the studies about 62% of new exons in human were originated from
Alu elements, whereas a lower fraction (28%) of SINE exonization was found in rodents
[131]. Alu exons are enriched at the 5’ UTR to modulate the protein production and thus
have great impact on the evolution of transcriptome [130].
In addition to the role of exon duplication and SINE elements in exonization, several
studies have revealed that most of the new exons originated from nonrepetitive intronic
sequences [8, 135]. However, these studies were based on EST data which may contain
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biases due to the low and unbalanced sequence coverage along the genes. In addittion,
most of the current studies have focused on only one aspect of the exonization mechanisms
with limitations in the data used. Thus, more comprehensive analysis on deep sequencing
data is needed to validate and further explore the potential factors that may contribute to
the emergence of new exons.
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5 Cancer transcriptome
Cancer is one of the severe diseases that causes human deaths worldwide. Up to now,
over 100 different types of cancers have been found in humans. Based on their sites
of origin, cancers can be classiﬁed into several main categories, including carcinoma,
sarcoma, melanoma, lymphoma and leukemia, which are derived from epithelial cells,
connective tissues, melanocytes, lymphocytes and the blood-forming tissue of the bone
marrow, respectively [136].
Unlike their nonmalignant precursor cells, cancer cells grow uncontrollably, escape cell
senescence or apoptosis, invade irregularly into surrounding tissue and other parts of the
body and eventually cause organ dysfunction and death of the host [137]. As early as
1915, Yamagiwa and Ichikawa introduced cancer into the skin of lab animals by repeated
application of coal tar [138]. Since then, the damage cuased by solar radiation has been
linked to high risk of melanoma, and the infection of Epstein-Barr virus (EBV) was
found to associate with several speciﬁc types of lymphoma [139]. Accumulated studies
demonstrate that many types of cancer can arise from exposure to environmental factors,
such as chemicals, radiation, infectious diseases and lifestyle [140]. In addition, the
predisposition to some cancers can also be inherited, such as breast cancer, ovarian cancer
and melanoma [141, 142]. For example, the well-known BRCA1 and BRCA2 mutations
associate with >75% risk of breast and ovarian cancers.
Cancer research is multidisciplinary as cancer-associated alterations are found at all levels,
such as genetic, epigenetic, transcriptomic and proteomic levels [14, 3, 1, 2]. Genome
instability, deﬁned as increased genetic alterations including mutations in nucleic acid
sequences, microsatellites and chromosomes [143], and epigenetic changes, such as
histone modiﬁcation and DNA methylation, are thought to be important factors that cause
the transcriptomic changes [144, 145]. The characteristics of the cancer transcriptome is
the focus of this section.
5.1 Transcriptional dysregulation in hallmarks of cancer
It has been widely accepted that tumor pathogenesis is a multistep process of cell transition.
From normal tissue state to a neoplastic tumor state, this carcinogenic transition exhibits
many traits that enable a normal cell to become extremely malignant [137]. Therefore, the
concept of cancer hallmarks were proposed and have gained much research interest.
Genome instability is one of the enabling characteristics of cancer [137]. Mutations can
alter the function of key proteins in cellular processes. For example, the oncogenic effects
of mutated p53 have been found in many cancers [146]. As genes are frequently mutated
in cancer and cancer cells evolve progressively with random mutations, it is challenging
to discriminate whether a mutation is a driver or a passenger [147, 148, 149]. However,
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genetic alterations can alter the transcriptional networks, which directly interact with
cancer-associated pathways. Identiﬁcation of transcriptional dysregulation is essential in
understanding the key mechanisms associated with cancer development, progression and
metastasis. Here, examples of transcriptional dysregulation are illustrated in each hallmark
of cancer.
5.1.1 Self-prompting of cell growth
Normal tissues maintain their functions by releasing growth signals to strictly control
the growth and division of normal cells. However, cancer cells can ignore or alter the
external signals and stimulate their own growth. The growth signals are often passed
through receptors located at the cell membrane. Expression alterations of cell membrane
receptors have been frequently reported in human cancers. For instance, overexpression of
the epidermal growth factor receptor (EGFR), a cell membrane receptor of growth factors,
has been identiﬁed in many cancers to promote the tumor growth and has been linked to
more aggressive tumor progression [150, 151, 152]. Blocking the activation of EGFR has
been shown to inhibit the growth of cancer cells in many cancers [150, 153, 154].
5.1.2 Evading anti-growth signals
In addition to the growth signals, cancer cells can negatively respond to the anti-growth
signals from their surrounding environment and keep growing. The typical growth
inhibitors include many tumor suppressor genes, such as TP53 and RB [155]. The
normal function of tumor suppressor genes is to inhibit abnormal growth. In cancer,
tumor suppressor genes are often inactivated to promote tumor growth and progression
through loss-of-function mutations or down-regulation of their expression. Several factors
contribute to the expression silencing, including epigenetic modiﬁcations, microRNAs and
interactions with upstream regulators [156, 157, 158]. Decreased expression of tumor
suppressor genes has been found in many cancers associated with poor prognosis, such as
breast cancer, acute lymphoblastic leukemia and neuroblastomas [159, 160, 161].
5.1.3 Resisting apoptosis
Apoptosis, programmed cell death, is a natural intracellular process to control the cell death
in order to maintain the normal cell populations in tissues. Unlike normal cells, cancer cells
are capable of ignoring apoptosis signals and evading cell death. Deregulation of apoptosis
related genes contributes to apoptosis evasion. For example, overexpression of BCL2, an
anti-apoptotic gene, is common in human cancers and associates with chemoresistance
[162]. In B-cell lymphoma, elevated expression of p53 inhibitor MDM2 protects cancer
cells from programmed cell death and contributes to the B-cell lymphomagenesis [163].
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5.1.4 Sustaining replicative immortality
Normal cells undergo growth and division within a limited number of cycles, which
eventually triggers senescence and apoptosis. Senescence is a process in which cells
lose the ability to proliferate in culture and remain viable only for a limited time [137].
Telomeres, the counting machine for cell aging located at the ends of each chromosome,
are shortened during each cell division, which triggers the senescence [164]. Cancer cells
are able to evade these limits and replicate immortally. Overexpression of telomerase,
an enzyme that maintains the length of telomere, correlates with the expression level of
the telomerase gene hTERT and has been observed in a vast majority of human cancers
[165, 166]. Telomerase has been considered as a potential therapeutic target for cancer
therapy.
5.1.5 Promoting angiogenesis
Angiogenesis is a process through which new blood vessels are generated from existing
vasculature. It occurs throughout the human body and is an important process to supply
cancer cells with enough oxygen and nutrients to maintain progression. Angiogenesis
can be stimulated by inducers, such as vascular endothelial growth factors (VEGF) and
ﬁbroblast growth factor (FGF) [137]. Decreasing the expression of VEGF has been
shown to prevent angiogenesis and tumor growth, which creates therapeutic potential for
anti-cancer therapy [167].
5.1.6 Activating tissue invasion and metastasis
By changing the shape and the interactions with other cells as well as extracellular matrix
(ECM), cancer cells spread all over the body by invading to their surrounding tissues and
metastasizing to distant locations. Various key molecules associated with this process
exhibit signiﬁcant alterations at their expression level. Adhesion molecules associated
with cell-to-cell and cell-to-ECM adhesions, for example E-cadherin and ICAM, are often
down-regulated in metastatic cancer cells [137, 168, 169], whereas cell migration related
molecules, such as N-cadherin, are frequently overexpressed [137]. Although alternative
mechanisms may exist, epithelial-mesenchymal transition (EMT) is a known process to
regulate cancer cells’ invasion and metastasis. Aberrant expression of several transcription
factors regulating EMT and metastasis has been observed. For example, overexpression
of transcription factors SNAIL, ZEB and TWIST, which directly or indirectly repress
the expression of E-cadherin, induce the EMT and invasion/metastasis related processes
[170].
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5.1.7 Evading immune system and metabolic reprograming
In recent years, many studies have suggested that cancer cells have the ability to both
escape from the surveillance of the immune system and alter their own energy metabolism.
The transcriptional dysregulation of genes involved in these processes has been shown to
closely connect to cancer developement. For instance, expression alterations of several
genes of the immune system, such as MHC-I and HLA-G, induce immune evasion and
tumorigenesis [171, 172]. Many studies have also discovered that regulation of genes
involved in glutamine metabolism changes to produce energy required for cancer cells
[173, 174].
5.2 Cancer transcriptome proﬁling
DNA microarrays and RNA-sequencing have generated large amounts of data for cancer
transcriptome study. Increasing numbers of transcriptome proﬁling studies have observed
distinct expression patterns between tumor and normal tissue samples. Cancer-speciﬁc
mRNA and miRNA level signatures identiﬁed by Zadran et al. clearly distinguished
diseased and healthy patients in multiple cancer types, including prostate, ovarian, breast
and lung cancers [175]. In the latest systematic study of ovarian cancer transcriptome,
Barrett et al. discovered tumor-speciﬁc isoform signatures with potential use in ovarian
cancer targeted therapy [176]. Transcriptome proﬁling of lung cancer by deep sequencing
revealed 111 lung cancer-associated lncRNAs playing important roles in tumor cell
proliferation [177]. Functional analyses, such as Gene Ontology and network analysis, on
cancer-speciﬁc signatures have revealed many important modules associated with tumor
initiation and progression, which provides comprehensive insights into the regulatory
changes of cancer transcriptome [178].
5.2.1 Cancer transcriptome commonalities
The Cancer Genome Atlas (TCGA) research network and other cancer genome consortiums,
such as the International Cancer Genome Consortium (ICGC), have created large amounts
of array and sequencing data at multiple levels for a large number of human cancers.
This gives a great opportunity to study the differences and commonalities systematically
across different cancer types. The COCA (cluster-of-cluster assignments) classiﬁcation
identiﬁed 13 integrated subtypes in 3527 tumor samples from 12 cancer types collected in
the Pan-Cancer project. Most samples in the subtypes correlated with their tissue origins,
such as kidney renal clear cell carcinoma, uterine corpus endometrioid carcinoma, ovarian
cancer, glioblastoma and acute myeloid leukemia, and were distinguished by integrated
molecular signatures at mutation, copy number, methylation, miRNA, mRNA and protein
levels [179].
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Cancer samples from different tissue origins can share common features at different levels.
In the case of genomic instability, high-grade serous ovarian cancer, basal-like breast cancer
and squamous-like carcinomas share frequent TP53 mutation and copy number changes;
a subset of breast and ovarian cancer patients carry BRCA1 and/or BRCA2 mutations
which are associated with patient survival; some patients from glioblastoma, gastric, serous
endometrial, bladder and lung cancers carry mutated ERBB2-HER2 and can respond to
HER2-targeted therapy [14, 179].
Clustering of gene expression data from the tumor samples in the Pan-Cancer collection
revealed eight clusters [180]. The largest cluster with samples from eight tissue ori-
gins, including acute myeloid leukemia (LAML), bladder urothelial carcinoma (BLCA),
breast invasive carcinoma (BRCA), colon and rectum adenocarcinoma (COADREAD),
glioblastoma multiformae (GBM), head and neck squamous cell carcinoma (HNSC), lung
squamous cell carcinoma (LUSC), ovarian serous cystadenocarcinoma (OV) and uterine
corpus endometrioid carcinoma (UCEC), is characterized by stroma-related signatures,
which indicates the common contribution of tumor microenvironment to the progression of
cancer cells. Another dominating cluster with tumor samples from six tissue origins, includ-
ing LUSC, lung adenocarcinoma (LUAD), HNSC, OV, GBM and BLCA, harbors TP53
mutation, genomic loss of CDKN2A (p16ARF), increased number of DNA double strand
breaks and upregulated signatures associated with cell cycle activation and proliferation,
implying the common mechanism of increased cell proliferation in response to the evasion
of DNA damage induced apoptosis caused by TP53 mutation [179, 180]. In addition to the
conserved proliferation signature, several studies have also identiﬁed common expression
patterns among different cancer types, including interferon-responsive signature in breast
and lung cancer [181], and common gene signature, including overexpressed AKT3 and
MYC, between basal-like breast cancer and high-grade serous ovarian cancer enriched
in oncogenic regulatory networks, such as HIF1-α/ARNT, MYC and FOXM1 pathways
[1]. A recent study on lncRNAs using a large patient cohort discovered a set of lncRNAs,
which have conserved oncogenic and tumor suppressive roles, share conserved expression
pattern across eight solid tumors [182]. Identiﬁcation of cancer commonalities can beneﬁt
the clinical decision making by suggesting common therapeutic approaches for cancer
treatments.
5.2.2 Cancer heterogeneity
Cancer is not a single disease. Instead, it is a heterogeneous group of diseases encompassing
a series of different histological and molecular subtypes. The TCGA research network
has completed a comprehensive analysis using multi-level data for several types of cancer
from their collection and identiﬁed different subtypes within each cancer. For example,
transcriptional proﬁling of high-grade serous ovarian cancer exhibited differentiated,
immunoreactive, mesenchymal and proliferative subtypes typiﬁed by the expression
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of genes involved in cell differentiation, immunoreaction, mesenchymal transition and
proliferation processes [3]; and consensus clustering on gene expression data revealed
classical, mesenchymal, proneural and neural subtypes in glioblastoma with altered
expression of EGFR, NF1, PDGFRA/IDH1 and neural-associated markers, respectively
[183]. In addition, robust subtypes were seen in cancers by data integration from multiple
platforms. For instance, luminal A, luminal B, HER2-enriched and basal-like subtypes
were identiﬁed in breast cancer [1], and four subtypes with Epstein-Barr virus-positive,
microsatellite instability, genomic stability and chromosomal instability were observed
in gastric cancer [2], revealing clear distinctions in their transcriptomic proﬁles. The
heterogeneity makes cancer a complex disease under alternative regulations, causing many
challenges in cancer treatment.
5.3 Cancer therapeutic resistance
The common options for cancer treatment include surgery, chemotherapy, radiation therapy,
hormonal therapy and targeted therapy. Surgery is an efﬁcient way to increase survival by
removing primary tumors before the tumor cells metastasize into other parts of the body.
The tumor specimen obtained from the surgery is often used for staging to determine the
disease status and the choice of other treatment options. Radiation therapy can be applied
to all solid tumors to kill the cancer cells and shrink the tumor size. However, many normal
cells and tissues surrounding the treated areas may also be affected by the radiation which
may induce side effects.
Chemotherapy uses cytotoxic drugs to destroy rapidly dividing cells, including cancer
cells. It is a common treatment approach applied to patients before surgery (neoadjuvant
chemotherapy) or after surgery (adjuvant chemotherapy). Hormonal therapy is often used
on hormone-sensitive tumors, such as breast cancer and prostate cancer, by adjusting the
level of hormones in the body. Targeted therapy is a relatively new approach in the ﬁeld of
cancer therapy, which uses speciﬁc agents to deregulate the target proteins with aberrant
expression and/or genomic/structural alterations essential for the survival of the cancer
cells.
Although chemotherapy and targeted therapy are the principal therapeutic methods for
cancer, drug resistance is a common severe obstacle that causes treatment failure. A
resistant cancer cell shows various types of novel characters, such as overwhelming
activation of drug target genes, enhanced pro-survival signaling, altered drug transport and
metabolism, high invasive transition, remodeling of tumor micro-environment and so on
[13]. According to classical evolutionary thought, drug resistance can be classiﬁed into
two types: intrinsic or acquired, which correspond to Darwin’s “natural selection” and
Lamarck’s "transmutation", respectively.
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5.3.1 Intrinsic resistance
Since 1970s, it has been demonstrated that there are subsets of cancer cells within tumors,
and these tumor subsets have different responses to treatment [184, 185]. According to
the Darwinian Theory, due to tumor heterogeneity, the intrinsicly resistant subset exists
before receiving chemotherapy. Under exogenous attacks, such as cytotoxic drugs, a minor
subpopulation of the cancer cells from the original tumor carrying random mutations are
selected due to their ability to survive the attack and grow into dominant clones [13].
For example, ERBB2 ampliﬁcation in breast cancer is used as a selection criteria for
trastuzumab treatment [186], and the high expression of ERBB2 is commonly identiﬁed
by immunohischemistry. However, heterogeneous distribution of ERBB2 overexpression
has been found in some breast tumors [187], which indicate decreased efﬁciency of
trastuzumab treatment.
As an extreme model of intrinsic drug resistance, cancer stem cells have been found
to be highly resistant to many therapeutic approaches [188]. Cancer stem cells are a
small subpopulation of tumor cells which are able to develop a new tumor. Unlike a
normal cancer cell, a cancer stem cell is relatively quiescent, and this characteristics
strongly weakens the efﬁciency of most chemotherapies, which preferentially target rapidly
dividing cells. In addition, cancer stem cells express high levels of anti-apoptotic proteins,
which activate pro-survival signaling molecules, and enhance vesicle trafﬁcking. All these
features endorse high resistance of cancer stem cells to drug therapy. Therefore, cancer
stem cells should be targeted in conjunction with current therapeutic approaches.
5.3.2 Acquired resistance
Several studies have claimed that chemo-resistance could be explained by Lamarckian
induction, a concept according to which characteristics are acquired for adaptation instead
of being pre-existing [189, 13]. Acquired drug resistance is developed during drug
treatment. The tumor itself is originally sensitive and transforms into a resistant subtype,
which may be caused by genetic mutations as well as various resistant responses. A recent
study by Pisco et al. identiﬁed that a small group of cancer cells alter their transcriptional
program to escape from the exogenous attacks [189].
During the progression toward malignancy, cancer cells require genetic mutations and
chromosome instability. The enhanced genetic instability is considered to be a hallmark
of cancer. Under the pressures of chemotherapeutic selection, cancer cell slow down the
replication rate due to damage to the DNA damage-repair mechanism, which helps the
cells to accumulate genomic instability and mutations. Eventually, the tumor exhibits
high heterogeneity due to cellular diversities, leading to different treatment responses. For
example, vemurafenib is efﬁcient for treating BRAFV600E -mutated melanoma, however,
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the resistant subsets shows acquired mutations in genes such as KRAS , NRAS and MEK1
[190, 191, 192].
5.3.3 Platinum-taxane combination chemotherapy for high-grade serous ovarian can-
cer
To achieve better treatment efﬁciency, many cytotoxic drugs are often given in a combi-
nation. A typical example is platinum-taxane combination chemotherapy. Platinum is an
anti-neoplastic agent, which can induce DNA damage and cellular apoptosis by forming
crosslinks in DNA, whereas taxane works by breaking the function of microtubules to
inhibit cell division. Platinum-taxane chemotherapy in combination with surgery is a
standard treatment approach for ovarian cancer [193, 194], the eighth most common cause
of female death from cancer worldwide. High-grade serous ovarian cancer (HGS-OvCa),
which is the most malignant type of ovarian cancer and originates from the fallopian tube
[195], accounts for 60-80% of all ovarian cancer cases [196] with ﬁve-year survival rate
less than 40% [197]. Although most of the HGS-OvCa patients initially respond to the
treatments, the majority relapses quickly within 18 months [198].
As described above, cancer is a heterogeneous disease with subgroups and alternative
regulation. The general chemotherapy often attacks the common features of cancer cells,
such as rapid cell division, but may not be speciﬁc to each subtype. Thus, subtype-speciﬁc
targeted therapy and/or in combination with chemotherapy appears to be a promising
strategy for precision medicine to overcome the chemoresistance present in subpopulations
of cancer patients [199, 200].
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6 Aims of the study
This thesis aims to develop comprehensive computational appproaches for the analysis of
high-throughput transcriptomic data. Application in mammalian and cancer transcriptome
data allowed to understand the complexity of transcriptome dynamics, the characteristics
of gene expression and alternative splicing, as well as the potential role of transcript-level
marker in the stratiﬁcation of treatment naive tumor samples for clinical decision making.
The speciﬁc aims in studies of Publication I - Publication IV were:
Publication I and Publication II: to develop a comprehensive analysis pipeline to identify,
quantify and classify mammalian exons, and to study their characteristics and underlying
regulatory mechanisms during the evolution of the transcriptome
Publication III: to develop a novel algorithm to solve the expression quantiﬁcation at
multi-levels for exon array data
Publication IV: to develop a novel method to stratify patients’ prognosis based on their
transcriptomic expression proﬁles from treatment naive tumor samples
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7 Materials and methods
In this chapter, the main expression data used in each study and the central computational
methods for analyzing these data are summarized. Detailed description on sample material
and each speciﬁc analysis are explained in each publication.
7.1 Biological material and methods
Table 1 summarizes the biological material and methods for the expression data sets used
in each publication.
Publication Material Species Methods
Publication I
Brain, colon, heart, kidney, liver,
lung, muscle, spleen and testes
tissue
Mouse,
rat,
macaque,
cow,
chicken
PolyA-selected RNA
sequencing
Heart, liver, testes, brain, colon,
skm, lung and kidney tissue [201]
Human PolyA-selected RNA
sequencing
Publication II Brain, colon, heart, kidney, liver,lung, muscle, spleen and testes
tissue [202]
Mouse,
rat,
macaque,
cow,
chicken
PolyA-selected RNA
sequencing
Publication III
Colon cancer primary tumors Human Exon array
HNSCC cell lines Human Exon array, qRT-PCR
Publication IV
TCGA OV primary tumors [3] Human Exon array
Other OV primary tumors [203, 204,
205, 206, 207, 208]
Human Gene expression
array
MUPET OV primary tumors Human qRT-PCR
MUPET OV primary cell lines Human Total RNA extracted
RNA sequencing,
in vitro cytotoxicity
assays
Table 1: Expression data sets and material used in each publication.
7.2 Expression quantiﬁcation for RNA-sequencing data
An overview of RNA-sequencing data analysis pipeline is illustrated in Figure 5, including
preprocessing, read mapping, expression quantiﬁcation and downstream goal-orientated
interpretative analysis. In preprocessing, FastQC [209] is a commonly used quality control
tool to assess the qualities of the sequenced reads, which can help determine the steps
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• Quality control 
• Barcode, adaptor, linker 
sequence removal 
• Trimming of poor quality 
sequences 
Preprocessing 
• Align reads to genome 
• Junction database 
• Re-align reads or unmapped 
reads to the junction database 
Read mapping 
• Quantification levels (gene, 
transcript, exon) 
• Quantification units 
(normalized counts, FPKM) 
Expression 
Interpretative 
analysis 
Raw reads 
Figure 5: The schema of RNA-sequencing data analysis pipeline.
needed for preprocessing. When barcode, adaptor and linker sequences are present in
the raw reads, they can introduce obstacles to the read mapping. Thus, they have to be
removed during this process. In addition, as the Illumina platform uses a sequencing
approach by synthesis, errors often accumulate towards the end of reads. Removing the
poor quality ends from the reads can also improve the efﬁciency of the read mapping. After
preprocessing, trimmed reads from each library are mapped to the genome respectively. To
make the results comparable, a second round of mapping is often executed using a junction
database merged from each library. The mapped reads from each library are then used as
input for expression quantiﬁcation at gene level using HTSeq for raw counts followed by
further normalization, such as counts-per-million with edgeR [210] and library-size factor
scaling with DESeq [211], or Cufﬂinks for fragments per kilobase per million (FPKM).
The commonly used tools in each step are listed in Table 2.
Module Function Tool
Preprocessing Quality control FastQC [209]
Barcode/adaptor/linker sequence removing Fastx Toolkit [212]
Poor quality trimming Trimmomatic [213]
Read mapping Mapping reads to genome TopHat [214]
STAR [215]
Expression Quantiﬁcation by FPKM value Cufﬂinks [216]
Quantiﬁcation by read counts HTSeq [217]
Read count normalization by counts-per-
million
edgeR [210]
Read count normalization by library-size
factor scaling
DESeq [211]
Table 2: Popular tools used in RNA-seq data analysis pipeline.
In Publication I and Publication II, we used TopHat for double-pass read mapping, where,
for each species, reads from each library were ﬁrst mapped to their respective genome
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(musmus9, ratnor4, rhemac2, bostau4 or galgal3) with Ensembl annotation v61 in novel
junction discovery mode and were once again mapped to their corresponding genome and
a junction database merged from each library of the same species. Cufﬂinks was then
used to assemble the transcripts in each library. Transcripts identiﬁed from each library
together with the Ensembl annotations were combined into a single transcript assembly
annotation for each species, which was then used as a reference annotation provided for
Cufﬂinks to run on all the libraries from the same species. The transcript expression were
quantiﬁed by FPKM values and the expression of transcripts with Cufﬂinks class codes of
"c" (contained), "j" (potentially novel isoform), "=" (complete match of intron chain), "e"
(possible pre-mRNA fragment) or "o" (generic exonic overlap with a reference transcript)
[216] were summed for overall expression at gene level. We used Percentage Splicing
Index (PSI) to measure the exon inclusion level for skipped exons. Exons were considered
as skipped when they were excluded in at least 1 detected transcripts with Cufﬂinks class
code of "j" or "=" with genomic coordinates sufﬁcient to include the exon. The PSI values
were then calculated by the FPKM values of transcripts that included the exon divided by
the overall expression of transcripts spanning the skipped exon region.
In Publication IV, the 2x100 base pair-end libraries from three patient-derived primary cell
lines (M022i, M068i and OC002) and one established cell line OVCAR8 sequenced with
HiSeq2000 were preprocessed using the standard RNA sequencing pipeline (Figure 5)
implemented in Anduril [218]. After quality control, 15 bp from the heading and 20 bp from
the tailing of the raw reads were automatically trimmed by Trimmomatic [213]. Trimmed
reads were then aligned to the human genome (hg19, Ensembl v75) by STAR [215] double-
pass read mapping. The aligned reads were then input to the expression quantiﬁcation
module following the Cufﬂinks pipeline [216] (Cufﬂinks-Cuffmerge-Cuffquant-Cuffnorm)
for gene expression quantiﬁcation in the form of fragments per kilobase per million
(FPKM).
7.3 Expression quantiﬁcation for microarray data
Affymetrix oligonucleotide microarray data are preprocessed in three steps: background
correction, normalization and summarization.
Several sources of signals, such as non-speciﬁc hybridization and ﬂuorescent artifacts,
can introduce signiﬁcant noise to the spot intensity quantiﬁed from the image analysis.
Thus, ﬁrstly, background intensities are removed from each probe to reduce the bias rising
from the unrelated interactions between probe and target sequences. The selection of
background correction models is platform dependent. For Affymetrix GeneChip exon
arrays, the commonly used models are global, PM-GCBG and MAT [219] which take the
exon array speciﬁc background probes in the model construction. For Affymetrix 3’IVT
arrays, such as U133a or U133 Plus 2.0, a normal-exponential foreground/background
model implemented in the Robust Multi-array Average (RMA) [220] is widely used.
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After background correction, normalization was carried out to correct for systematic
errors and biases in intensities between samples to make the samples comparable between
each other. Several normalization approaches are available, such as global mean/median,
lowess, quantile or those based on house-keeping genes and spike-in controls. Quantile
normalization [221], which assumes all the samples from each study share the same
distribution, is widely used for Affymetrix arrays, whereas lowess [222, 220] is often used
for Agilent arrays.
Given a set of background corrected and normalized probe intensities, multiple probe
intensities are combined into a single value to represent the expression of corresponding
features (probeset, exon, gene). Median polishing algorithm [220], which takes row
(sample) and column (probe) effects into account, was used to summarize the expression
at gene and exon levels.
7.4 Mammalian exon age assignments
We developed a comprehensive pipeline to assign genomic age and splicing age for
each exon. The genomic age measures the duration over which the exon’s homologous
sequences were present in the ancestral genomes, whereas the splicing age estimates the
duration over which the exon was expressed in the ancestors. An example illustration on
the concepts of genomic age and splicing age is shown in Figure 6.
We selected exons for this analysis based on the following criteria. Firstly, as we are
interested in splicing events rather than alternative transcriptional initiation or alternative
polyadenylation, exons located at the internal gene regions were selected. Secondly, as gene
duplication and exon duplication inside a gene can complicate the exon age assignments,
we used exons from single-copy genes and removed exons from intra-genic duplication.
Thirdly, as genes with low expression may introduce signiﬁcant bias to the downstream
interpretative results, we only consider exons from genes with expression FPKM ≥ 2.
We used whole-genome multiple alignments from PECAN and EPO [223] together with
pairwise alignments from BLASTZ [224] to search for homologous regions in other
species for each exon. Due to the possibility of missing alignments with these methods,
which may introduce bias to the age assignments, we re-mapped all the exons which do
not have any homologous regions found in chicken to all the species using BLAT [225].
The genomic age for each exon was then deﬁned based on the pattern of aligned regions in
each species and the precomputed species tree [135] using parsimony, which assumes the
minimum number of changes during the evolution. Similar to genomic age assignments,
we assigned the splicing age to each exon based on the expression pattern of aligned
regions in each species. In our study, we only consider exons with unique parsimonious
age assignments.
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Figure 6: Illustration on the genomic age and splicing age of a mouse exon
(3:108240427:108240497:-, genome build: musmus9). The multiple sequence alignments
of the mouse target exonic region in ﬁve species are shown on the left and the precomputed
species tree is demonstrated on the right. The expressed regions are colored in red. For the
genomic age, there are homologous regions present in rat, macaque, cow and chicken, and
thus the genomic age for this mouse exon was assigned to be 300+. For the splicing age,
the aligned homologous regions were spliced into mRNAs in rat, macaque and cow, and
thus the splicing age for this mouse exon was assigned to be 100-300.
7.5 Survival analysis
Survival analysis is a set of statistical methods for handling time-to-event data and is
widely used in medical and epidemiological studies [226]. It depends on two components,
time to events and vital status. The common examples of time-to-event are the time to
the occurrence of death or the recurrence of a disease. The vital status records the event
status at the time of observation. In many cases, the observations on time-to-event are
incomplete, meaning that the actual time when the event occurred is not known. This could
be caused by the loss of follow-up data before the tracking period ends. These observations
are called "censored". Survival methods can take all censored and uncensored observations
into account and estimate the model parameters. An example of censored and uncensored
cases is shown in Figure 7.
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Start of study                                                                    End of study 
Censored observation 
Uncensored observation 
(Event) 
Figure 7: Illustration of censored and uncensored observations in survival data.
There are two types of functions in survival analysis: survival function and hazard function.
Survival function estimates the probability of surviving up to time t, whereas hazard
function estimates the probability of dying per time unit given that the individual has
survived up to time t. Survival methods can be classiﬁed into parametric, semi-parametric
and non-parametric methods. The most popular methods are non-parametric Kaplan-Meier
product limit estimator [227] and semi-parametric Cox proportional hazard model [228].
Kaplan-Meier survival estimator
Kaplan-Meier survival analysis estimates the probability of surviving from a sequence
of time intervals. In the ﬁrst step, the observed times are ranked in an increasing order
and intervals are formed. Each interval starts with the observed time and ends with the
time just before the next observation, denoted as [ti, ti+1) where i is the ordered index.
The conditional survival probability through each interval is calculated by ni−dini , where
ni is the number of individuals at risk and di is the number of events observed. Censored
observations within a time interval contribute to the number at risk for that interval but are
not considered for the next time interval. The estimated survival probability at each time
point is then calculated by the conditional survival probability at that time multiplying the
conditional survival probabilities from the preceding intervals as shown in equation 1.
The Kaplan-Meier estimates of survival function can be visualized by survival curves with
survival time in years, months or days on the x-axis and the estimated survival probability
on the y-axis. Log-rank test is a widely used method for comparing the survival estimates
from Kaplan-Meier between groups.
ˆS(t) =Πti≤t
ni−di
ni
(1)
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Cox proportional harzards model
Cox model is a regression method to investigate the effects of single variable (univariate
regression) or multiple variables (multivariate regression) on survival. Instead of estimating
the survival probability at the time of interest as in Kaplan-Meier, it estimates the probability
of experiencing an event from a hazard function (equation 2), where βi and xi represent
the coefﬁcient and the value of the i-th variable, respectively.
h(t) = h0(t)exp(β1x1+β2x2+ ...+βkxk) (2)
The hazard ratio (HR= h(t)ih(t) j ) of an explanatory variable measures the hazard rate differ-
ences between two groups and can be estimated from the exponent of its coefﬁcient (eβ ).
A positive coefﬁcient for an explanatory variable means that patients from group i have
a higher risk of death than those from group j, whereas a negative coefﬁcient indicates
that patients from group i have a better prognosis than those from group j. In proportional
hazards regression, it is assumed that the hazard ratio is a constant at any time point.
7.6 Linear predictor score
The linear predictor score (LPS) was ﬁrst introduced in the diffuse large B-cell lymphoma
study to differentiate ABC and GCB subtypes [229]. Each sample is assigned a linear
predictor score in the form of LPS(X) =∑
i
ai×Xi, where ai is the scaling factor for gene
i and Xi is the expression of gene i. The scaling factor is estimated for each gene from the
training set where the subgroups are known and is calculated from the t statistics, which
measures the degree of discrepancy on gene expression between the two subgroups.
As LPS values are formed from linear combination of gene expression values that are
approximately normally distributed, the distribution of LPS values in each subgroup can
then be estimated from the training set. By giving the mean and variance of LPS in
each subgroup, a new sample can then be assigned to the subgroup using the Bayes’ rule
(equation 3), where μ1, σ21 represent the mean and variance of LPS in subgroup 1 and μ2,
σ22 are the mean and variance of LPS in subgroup 2 of the training set.
P(X in subgroup 1) =
φ(LPS(X);μ1,σ21 )
φ(LPS(X);μ1,σ21 )+φ(LPS(X);μ2,σ
2
2 )
(3)
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8 Results
In this chapter, the main results on the studies of transcriptome dynamics in mammals and
human cancer are summarized.
8.1 Identiﬁcation of mammalian exons
Exons from mouse, rat, macaque, cow and chicken quantiﬁed from the deep RNA
sequencing data were compared with the existing annotation (Ensembl version 61) for
each species. We detected 97%, 97%, 90%, 97% and 99% annotated exons in mouse, rat,
macaque, cow and chicken, respectively, which belong to 83%, 90%, 91%, 94% and 97%
annotated protein-coding genes in Ensembl.
By comparing to existing exon annotations from Ensembl, GeneBank, RefSeq and EST,
we detected many putative novel (unannotated) exons that had not been reported earlier. Of
the Cufﬂinks annotated putative exons, 28,133, 49,637, 59,914, 59,356 and 62,467 exons
from mouse, rat, macaque, cow and chicken were unannotated in protein-coding genes;
1,167, 1,939, 4,388, 1,518 and 2,143 exons were unannotated in novel spliced transcripts of
known genes which were not connected to any annotated exons; 4,060, 6,750, 4,409, 4,465
and 5,729 exons were unannotated in spliced transcripts antisense to known genes and
10,247, 24,433, 8,837, 19,364 and 19,230 exons were unannotated in spliced transcripts
that do not belong to any known genes.
Internal exons from singleton genes of each species were used in Publication I and
Publication II.
8.2 The characteristics of ancient exons
8.2.1 Ancient exon classiﬁcation by the age of alternative splicing
In Publication I, we analysed ∼48,000 mouse internal exons from singleton orthologous
genes that were conservatively expressed in chicken and at least two mammals. Ancient
mouse exons were assigned to different categories using a one-letter code for four species,
where C, Q, R and M indicates alternative splicing in cow, macaque, rat and mouse
respectively; c, q, r and m indicates constitutive splicing observed in cow, macaque, rat
and mouse respectively. Exons with alternative splicing observed in mouse alone were
assigned to the group of species-speciﬁc gain of alternative splicing termed as cqrM. Exons
with alternative splicing observed in mouse and rat but not in other species were considered
as rodent-speciﬁc gain of alternative splicing termed as cqRM. Exons with alternative
splicing observed in all the species were classiﬁed into alternative splicing in mammals
group (CQRM), whereas exons constitutively expressed in all the species were assigned
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into constitutive splicing in mammals group (cqrm). Similarly, exons with alternative
splicing observed in cow, macaque and rat but not in mouse or with alternative splicing
observed in cow and macaque but not in mouse and rat were considered as species-speciﬁc
loss of alternative splicing termed as CQRm or rodent-speciﬁc loss of alternative splicing
termed as CQrm. Exons that could not be classiﬁed were grouped into "complex" category.
The numbers of exons assigned to each category are shown in Table 3.
Table 3: The number of mouse ancient exons in each age category of alternative splicing.
Gain of AS Loss of AS
Exon category cqrm cqrM cqRM CQRM CQRm CQrm complex
Counts 38257 1691 310 489 29 186 468
8.2.2 The characteristics of ancient alternative exons
To investigate whether there are any differences in the evolutionary patterns between gene
expression and exon splicing, we applied hierarchical clustering based on Jensen-Shannon
divergence (JSD) distance [230] on gene expression data of orthologous singleton genes
broadly expressed in chicken and all the other species and PSI values of exons with
alternative splicing detected in all the mammals under this study.
The clustering of samples based on the gene expression exhibits a "tissue-dominated
clustering" pattern in eight tissues (lung, kidney, brain, spleen, testes, liver, muscle
and heart). An exception was found in chicken, where tissues with similar cell type
compositions tend to cluster together (for example, muscle and heart samples). This
suggests the divergence of species-speciﬁcity in gene expression starts to outpace tissue-
speciﬁcity at a phylogenetic distance of ∼300 million years, which corresponds to the
divergence between chicken and mammals.
At the level of splicing, a "tissue-dominated clustering" pattern was observed for exons
expressed in brain and in the combination of heart and muscle, which suggests a high
conservation of alternative splicing signature in these tissues. Conversely, we discovered
a clear "species-dominated signature" for exons expressed in the remaining ﬁve tissues
(colon, kidney, liver, lung and spleen). This indicates that lineage-speciﬁc changes in
cis-regulatory elements and/or trans-acting factors are the dominant factor affecting the
alternative splicing patterns, while tissue-speciﬁc changes have a larger effect on the gene
expression than on splicing.
Interestingly, we observed an increasing trend of tissue-speciﬁcity and sequence conserva-
tion within exons and their neighboring intronic regions along with the phylogenetic breadth
of alternative splicing. The observation of tissue-speciﬁc regulatory motifs enriched in
ancient alternative exons relative to constitutive exons indicates that the splicing regulation
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of these exons may rely on splicing regulators, which are often expressed in a tissue-
speciﬁc manner. In addition, an enrichment of phosphorylation sites seen in tissue-speciﬁc
alternative exons indicates a potential of tissue-speciﬁc alternative exons in altering the
protein phosphorylation status.
8.3 The origin of new exons
In Publication II, to investigate how the new exons were created during evolution, we
classiﬁed unduplicated internal exons from single-copy genes based on their genomic age
and splicing age for each species (mouse, rat, macaque and human). This resulted in 1,089
mouse, 1,571 rat, 1,417 macaque and 2,073 human species-speciﬁc exons, respectively.
The number of exons belonging to each age group is shown in Table 4 and Table 5.
Table 4: The number of exons in each genomic age group.
Species 0-25 25-90 90-110 110-300 300+
Mouse 17 237 598 4764 49694
Rat 22 342 623 4682 46487
Macaque 4 237 239 4106 40402
Human 12 156 242 5313 45679
Table 5: The number of exons in each splicing age group.
Species 0-25 25-90 90-110 110-300 300+
Mouse 1089 361 792 4868 47750
Rat 1616 401 736 4633 44293
Macaque 1419 506 505 3871 38417
Human 2073 231 636 4553 43613
Species-centric analysis revealed distinct properties of exons with different splicing ages.
Species-speciﬁc exons were 1) largely alternative spliced and located in the 5’UTR while
ancient exons were mostly constitutively spliced and within protein coding regions, 2)
more often included in testes than other tissue types, 3) included in various types of genes
but not in genes belonging to a certain functional category, and 4) more polymorphic in
individuals than exons from other age groups.
8.3.1 Species-speciﬁc exons mostly came from unique intronic sequences
To trace the sequence origins of the species-speciﬁc exons, we classiﬁed their aligned
orthologous regions in the closest species based on the types of genic regions and repeat
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classes. From the classiﬁcation on genic regions, we found that most of the species-
speciﬁc exons came from the intronic sequences of orthologous genes while the rest
came from proximal intergenic regions and regions in other genes not belong to the same
family. Regarding repeat classes, about half of the species-speciﬁc exons originated from
sequences unique in the genome, whereas the rest came from repeated elements including
SINE, LINE, LTR and other types, which was inconsistent with previous studies stating
that new human exons were originated from repeated elements. However, comparing to
genomic background of each repeat class, a larger proportion of new exons came from
SINE elements than from the other repeat classes.
8.3.2 Factors contributing to exon creation
We compared the splice site dinucleotides of mouse-speciﬁc exons and their aligned
proto-exons in rat. Almost all the mouse-speciﬁc exons had minimal splice site sequences
(GT/GC at 5’ splice site and AG at 3’ splice site). About half of the proto-exons did
not contain these minimal splice sites indicating that mutations creating the splice site
dinucleotide may contribute to the creation of 50% of the new exons in mouse.
Since half of the rat proto-exons contained minimal splice site sequences but they were not
spliced in rat, we hypothesized that there might be additional factors contributing to the
exon creation. We searched for splicing regulatory elements in mouse-speciﬁc exons, rat
proto-exons and their neighboring intronic regions. We observed a higher density of exon
splicing enhancers (ESEs) in mouse-speciﬁc exons and intronic splicing enhancers (ISEs)
in upstream and downstream of mouse-speciﬁc exons than in rat proto-exons and adjacent
intronic regions. In contrast, a signiﬁcantly lower density of exon splicing silencers (ESSs)
was seen in mouse-speciﬁc exons than in aligned rat proto-exons. These indicate that
mutations arising in the splicing regulatory regions may also contribute to the creation of
new exons.
Interestingly, we found that the distance between the ﬂanking exons of rat proto-exons
is longer by 1.3 fold than that of mouse-speciﬁc exons. Same trend was seen in rat-
speciﬁc exons, where the distance between the ﬂanking exons of mouse proto-exons is
1.7 fold longer than that of rat-speciﬁc exons. By comparing the lengths of upstream
and downstream introns, we found that downstream introns of mouse-speciﬁc exons are
1.2 fold longer than the corresponding upstream introns, whereas no difference was seen
in rat proto-exons. Similar length bias was observed in rodent-speciﬁc exons but not in
their proto-exons in macaque and older exons. These altogether indicate that deletion of
upstream intronic sequences is one of the key factors compensating the shortage of other
splicing determinants contributing to the new exon inclusion.
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8.3.3 Increased nucleosome occupancy and RNA Pol II pausing on new exons with
upstream Indels
As a proportion of new exons were included under selection pressure by the deletion of
upstream intronic sequences, we further explored the association to this phenomenon at the
chromatin level. Surprisingly, we observed that new exons with upstream deletions have
stronger nucleosome enrichment and RNA Pol II pausing compared to the exons without
indels and to the ancient exons. The connection between upstream intron deletion and
enriched nucleosome occupancy on exons is further validated in an independent dataset of
human lymphoblastoid cell lines with sQTLs and MNase-seq data available from a number
of individuals [231]. These results suggested that the inclusion of new exons could be
strengthened by shifting the nucleosome positioning and slowing RNA Pol II elongation
via deletions in upstream intronic sequences.
8.3.4 Inclusion of new exons is associated with increased gene expression
We evaluated the effects of new exon inclusion on gene expression by comparing the
expression of genes that 1) contain mouse-speciﬁc exons expressed in mouse tissues with
rat orthologs in the same tissues of rat, 2) contain species-speciﬁc (mouse and rat) exons
expressed in tissues with orthologs in aligned closest species (rat and mouse) without a
new exon included in the corresponding tissues binned by the exon inclusion level (PSI),
3) between mouse and rat where an ancient exon became skipped in mouse, 4) between
mouse and rat where an ancient exon became skipped in mouse binned by the PSI values
of exons, and 5) between mouse and rat where an ancient exon became skipped in mouse
binned by the location of the exon in gene. The comparison results altogether pointed
to the same direction that the inclusion of new exons can enhance gene expression in a
dose-dependent manner, and bigger effects were shown in exons located at the 5’ end than
those at the 3’ end of the gene.
8.4 MEAP: an array-based expression quantiﬁcation method for alter-
native splicing
Different from the conventional gene microarrays with probes targeting the 3’ end of
genes for measuring the overall expression of gene transcripts, probes on exon arrays
were designed to map to different regions along the gene body, which makes it feasible
to measure the expression of exons to quantify the expression of each alternative splicing
variant. Several sources of bias could introduce deviations to the expression values, for
example outdated gene annotations and array background noise which may come from
substrate contamination [232]. Background adjustment is a challenging step in array
data preprocessing as background signals vary from probe to probe. In addition, some
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approaches, such as splicing index, have been widely used in the study of alternative
splicing from exon array data. They often output the splicing events signiﬁcantly altered
in certain biological conditions without providing absolute quantitative expression values
for each sample at exon, splicing variant and gene levels. Thus, there is a need for new
computationally efﬁcient methods for accurate expression quantiﬁcation at multi-levels
from exon array data.
We developed the multiple exon array preprocessing (MEAP) algorithm, which includes
novel models for probe background correction and expression quantiﬁcation at alternative
splicing variant level as well as at the exon and gene levels. The parallelization implemented
in MEAP makes it computationally efﬁcient to process hundreds of samples within a short
time period. Additionally, to reduce the potential bias from old gene annotations, we built
a new probe annotation for MEAP by aligning probe sequences to the latest genome build
and extracted probes with unique perfect match to exonic regions.
8.4.1 PM-BayesBG model for background correction
Affymetrix exon array contains a pool of genomic and antigenomic background probes
designed to target the overall background noise. MEAP PM-BayesBG model estimates the
background signal of a given probe sequence by applying a naive Bayesian approach in
equation 4
P(θi|s) = P(θi)×L(s|θi)N
∑
j=1
P(θ j)×L(s|θ j)
=
P(θi)×L(s|θi)
C
=
Ni×∏25j=1 pi,s j
N×C (4)
, where θi, s, P(θi) and L(s|θi) denotes a background intensity, a probe sequence, the proba-
bility of the occurrence of a background intensity and the probability of the occurrence of a
probe sequence given a certain background intensity. PM-BayesBG utilizes the intensities
from background probes to construct the prior information (P(θi)) by discretizing the
sorted continuous intensity values into continuous intervals. The averaged intensities from
each interval are then used as the probe background intensity for each background intensity
class (θi), and P(θi) is calculated by the number of background probes within the intensity
interval divided by the total number of background probes on the array (NiN ). In addition
to the prior information, PM-BayesBG calculates the likelihood for the i-th background
intensity class (L(s|θi)) using the base occurrence rate matrix (BORM) estimated from
the sequence contents of the background probes in each background intensity class in
the form of L(s|θi) =∏25j=1L(s j|θi) =∏25j=1 pi,s j , where s j is a nucleotide at position j in
a probe sequence and pi,s j is the probability of the nucleotide at position j in a probe
sequence belonging to a given background intensity class i. After interactively estimating
the posterior probability shown in equation 4, the background intensity of a given probe
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sequence is then estimated from the maximum posterior probability θˆ = maxiP(θi|s).
8.4.2 Expression quantiﬁcation at multi-levels
Besides the novel feature of background correction, MEAP can also quantify the expression
values at alternative splicing variant as well as exon and gene levels. Median polish, a
commonly used summarization method by conventional microarrays, is used in summa-
rizing the expression data at the exon and gene levels. At the exon level, intensities of
probes mapping to unique exonic regions based on MEAP annotations are summarized
into single intensity value for each exon. And at the gene level, only probes that map
to the majority of transcripts passing the transcript quality controls are used in the gene
expression summarization.
Different from exon and gene level expression summarization, we use QR decomposition
to quantify the expression of splicing variants from a linear least square regression model
AT = E built upon the information of exon expression (E) and exon-transcript structure (A)
for each gene, where E is a matrix with m rows and 1 column representing the expression
of each exon in a gene, T is a matrix with n rows and 1 column representing the expression
of each transcript in a gene, and A is a matrix with m rows and n columns indicating
the gene’s exon-transcript structure assuming a gene has m exons and n transcripts. An
example of a gene with three transcripts {t1, t2, t3} and three exons {e1,e2,e3} is shown in
equation 5 and 6.
t1+ t2+ t3 = e1
t1+ t3 = e2
t1+ t2 = e3
(5)
T = A−1E =
⎛
⎜⎝
1 1 1
1 0 1
1 1 0
⎞
⎟⎠−1×
⎛
⎜⎝
e1
e2
e3
⎞
⎟⎠=
⎛
⎜⎝
−e1+ e2+ e3
e1− e2
e1− e3
⎞
⎟⎠ (6)
In Publication III and Publication IV, MEAP quantiﬁed expression data at alternative
splicing level were used in the case study of head and neck carcinoma and high-grade
serous ovarian cancer.
8.4.3 Expression alterations in head and neck carcinoma
Head and neck carcinoma (HNSCC) is the sixth most common cancer type, accounting
for 6% of all cancer cases worldwide every year [233]. In HNSCC, the ampliﬁcation of
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the 11q13 region occurs in 30-50% of tumors [234] and is associated with higher tumor
grade, metastases and decreased survival [235, 236, 237]. Identiﬁcation of genes, exons or
alternative splicing variants signiﬁcantly differentially expressed between HNSCC tumors
with 11q13 ampliﬁcation (11q13+) and deletion (11q13-) may discover important factors
contributing to the poor outcome of HNSCC 11q13+ tumors.
We processed exon array data from 15 HNSCC cell lines, seven of which have 11q13+
and eight of which have 11q13-, with MEAP and three other widely used exon array
preprocessing methods (RMA, FIRMA and PLIER) at the exon level to compare the
quality of the summarized expression data. By comparing the two conditions, each method
produced a different number of differentially expressed exons (DEEs) with 12,650 DEEs
in total and 2,383 DEEs in common. The small fraction of common DEEs indicated the
results could be greatly affected by the choice of the exon array preprocessing methods. We
randomly selected four exons that were identiﬁed as DEEs (p< 0.05 and |log2(FC)| ≥ 1)
by using the MEAP quantiﬁed expression data and two exons that were not identiﬁed
as DEEs by most of the methods. The four MEAP-speciﬁc DEEs were signiﬁcantly
differentially expressed between 11q13+ and 11q13- HNSCC cell lines in the same
direction as expected in qRT-PCR validation. No signiﬁcant differences were found
for the other two exons. These demonstrated that MEAP is able to produce reliable
expression data for accurate identiﬁcation of differentially expressed exons.
In HNSCC, ampliﬁcation and overexpression of genes located at 11q13 are associated
with distant metastasis [238]. Several genes located at the 11q13 amplicon, such as
ORAOV1, ANO1 and PPFIA1, are known to be important in HNSCC and to have a
role in tumorigenesis, metastasis and progression [238, 239, 240, 241]. As alternative
splicing of these genes has not been well studied in HNSCC, we further investigated
the expression of their splicing variants in 11q13+ and 11q13- HNSCC cell lines with
MEAP. Two variants of ORAOV1, ORAOV1-201 and ORAOV1-203, were signiﬁcantly
up-regulated in 11q13+ samples, whereas ORAOV1-202 was expressed at a relatively low
level and did not show any expression differences between the sample groups. For ANO1,
a transmembrane protein acting as a calcium-activated chloride channel (CaCC) at the
plasma membrane, all the variants were overexpressed in 11q13+ samples. Two isoforms
of PPFIA1 exhibited imbalanced expression in the HNSCC cell lines, where PPFIA1-201
was expressed at a very high level and signiﬁcantly overexpressed in 11q13+ samples as
compared to PPFIA1-202 which was weakly expressed in all the cell lines. In addition, we
also searched for splicing variants located outside of the 11q13 amplicon region whose
altered expression were associated with the ampliﬁcation or deletion of chromosomal
region 11q13. In total, 330 splicing variants were identiﬁed as 11q13-speciﬁc. To evaluate
the expression of splicing variants quantiﬁed by MEAP, we randomly selected ORAOV1
from the 11q13 amplicon region and NEO1 located outside the 11q13 amplicon region
for qRT-PCR validation. Both showed altered expression at the alternative splicing level.
The consistent validation results further indicated that MEAP can be used for accurate
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expression quantiﬁcation. While more work is needed to study the functions of distinct
splicing variants in cancer, identiﬁcation of altered expression at the alternative splicing
level may reveal new factors essential for tumor development and progression.
8.5 PSFinder: an integrated approach utilizing expression and clinical
data for cancer transcriptome subgrouping
Cancer transcriptome proﬁling has revealed cancer as a heterogeneous disease with distinct
molecular subtypes [3]. In order to decipher the potential connections between the
subgroups and prognosis, we developed an integrated approach to identify co-expressed
features for patient prognostic subgroup stratiﬁcation (Figure 8). Given a set of samples,
PSFinder ﬁrst searches for features with expression associated to patients’ survival by
univariate Cox regression in combination with Kaplan-Meier survival analysis. Seeds with
correlated expression across the samples form cliques and are selected when they are able
to divide the samples into groups with signiﬁcant survival association. The initial cliques
are then iteratively merged when the subgroup division and survival association remain the
same. The outputs from the seed search, the initial clique collection to the clique merge
steps, are the features in the merged clique with the maximum score and the subgroups
stratiﬁed by them. PSFinder then starts from seed search, initial clique collection to
the clique merge on the subset of samples identiﬁed from the previous iteration until no
more features satisfy the criteria to further divide the samples into groups with survival
association. The ﬁnal output of PSFinder is all the features involved in the subgroup
stratiﬁcation and all the subgroups identiﬁed from the iterations.
8.6 Splicing variants as biomarkers for the stratiﬁcation of HGS-OvCa
prognostic subgroups
Splicing variants have been demonstrated to be better signatures than genes for the
discrimination of non-oncogenic and oncogenic samples [52]. Up to now, most of
the studies have indicated the theraputic potential of biomarkers at gene level for clinical
diagnosis [78, 79, 80]. Here in the application of PSFinder, we quantiﬁed the expression at
alternative splicing variant level with MEAP for 180 (discovery set) and 327 (validation set)
HGS-OvCa primary tumor samples from the TCGA repository. Patients from the discovery
set were treated with ﬁrst-line platinum-taxane combination therapy, whereas patients from
the validation set received some other chemotherapy in addition to the ﬁrst-line treatment.
PSFinder analysis on the discovery set at the splicing variant level revealed three subgroups
stratiﬁed by 61 splicing variants from 51 genes, two (Poor I and Poor II) associated with
decreased overall survival and one (Good) with improved overall survival (log-rank test
p=0.007). These splicing variants were strongly co-expressed within each sample and
exhibited very distinct expression proﬁles between the identiﬁed subgroups. The three
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Figure 8: The schema in PSFinder approach. PSFinder is an iterative rule-based approach,
which starts from all the samples in a cohort to a subset of samples, and ends when no
features exist to further divide the subset of samples into groups with survival association.
There are three main steps in PSFinder: seed search, clique collection and clique merge.
subgroups were validated in eight independent validation cohorts, including a prospective
cohort from the MUPET study.
The distinct expression proﬁles indicated distinct characteristics of Poor I and Poor II
subgroups. By comparing the PSFinder identiﬁed markers with genes involved in subtype
classiﬁcation by Tothill et al. [203], we found that high stromal gene expression is
a characteristic of Poor II subgroup whereas Poor I was not reported earlier. By data
integration at multiple levels, Poor I subgroup revealed an interesting pattern of elevated
promoter hypermethylation, which correlated with the overexpression of full length splicing
variants of de novo methyltransferase gene DNMT3B. After treating HGS-OvCa cell lines
with a demethylation reagent (Decitabine), greatest effects were seen in cell lines with
Poor I characteristics.
As BRCA1/2 mutation is a known risk factor on the survival of HGS-OvCa patients [242],
we further investigated the connection between BRCA1/2 mutation and the PSFinder
identiﬁed subgroups. No clear BRCA1/2 mutation enrichment was seen in any PSFinder
subgroups, which suggested that PSFinder subgroup may be a risk factor independent
of the BRCA1/2 mutation. Multivariate Cox regression analysis using patients’ clinical
parameters, such as age, grade, stage and residual disease, together with BRCA1/2 mutation
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status and PSFinder subgroups on overall survival further revealed the strong prediction
power of BRCA1/2 mutation and PSFinder subgroups on the survival of HGS-OvCa
patients. Stratiﬁcation of chemo-sensitive and chemo-resistant patients may beneﬁt the
clinical research to select right patients for future alternative therapeutic trials.
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9 Discussion
This thesis concentrates on the quantitative study of transcriptome dynamics by means of
theoretical and methodological research. The theoretical research on multiple mammalian
species showed the dynamic transcriptional changes during the species evolution, which
provides useful knowledge for method development. Two computational methods, MEAP
and PSFinder, developed from the methodological study exhibited new ways for expression
quantiﬁcation and cancer heterogeneity stratiﬁcation, which are two of the key research
questions in the transcriptomic studies. These new methods were applied to cancer
transcriptome data and the results were conﬁrmed in independent clinical specimens. In
combination with clinical validation, a novel chemoresistant subgroup in ovarian cancer
was discovered.
Earlier studies have shown that alternative splicing contributes to the differences between
species [243, 109]. In Publication I, we investigated the expression characteristics of
ancient alternative exons together with ancient genes by genome-wide comparative analysis
using RNA-seq data from tissues of multiple mammalian species. The clustering of tissue
samples based on the inclusion level of ancient alternative exons revealed a species-
dominated signature, which is in accordance with the observation from a parallel study
using organ transcriptome data from 11 vertebrate species spanning 350 million years
[110]. In contrast, clustering on the expression of ancient genes showed a tissue-dominated
pattern. These imply that alternative splicing may function as a driving force to the
evolution of mammals, whereas the expression of genes is regulated in a tissue-speciﬁc
manner.
Changes in cis-regulatory motifs and trans-acting factors contribute to the species-speciﬁc
pattern of alternative splicing [110]. Our in-depth analysis on ancient alternative exons
revealed their high tissue-speciﬁcity regulated by tissue-speciﬁc splicing factors and their
role in altering the protein functions. An interesting future direction would be the study of
altered protein-protein interactions so as to identify the functional modules contributing to
the phenotypic changes.
In addition to the study of broadly expressed alternative exons (Publication I), we system-
atically explored the new exons created during the evolution (Publication II). Previous
studies have found repeated elements, especially the SINE elements, are the major source
of new exons [9, 130, 131]. However, in our study, greater impact of intronic sequences
on exonization has been observed. Meanwhile, we also discovered a fraction of the new
exons originated from non-repeated intergenic regions. These discrepancies may result
from different sequence-based measurements used for the new exon quantiﬁcation.
We observed several factors that may contribute to the exon creation, including mutations
occurring in splice sites and splicing regulatory elements, and upstream intron shortening
associated with increased nucleosome occupancy and Pol II pausing. This is the ﬁrst study
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showing the effects of intron length on new exon creation, which links the interaction
between epigenetics and transcription. Moreover, we discovered the inclusion of new
exons, especially when they are located towards the 5’ end, can boost gene expression,
suggesting a new way to enhance gene expression for experimental research.
From our study, new exons are characterized as more alternative spliced, non-coding and
enriched at 5’UTR than ancient exons. This implies the potential regulatory roles of these
new exons in altering the gene expression. In-depth functional studies on the new exons
are required to understand their contribution to the species-speciﬁc differences.
Expression quantiﬁcation is central in transcriptomic studies. Thus, the MEAP algorithm
was developed to quantify the expression values at multiple levels from exon array data
(Publication III). In contrast to the standard methods for Affymetrix exon array data
preprocessing, such as RMA and PLIER [244], that estimate the probe background signals
based on intensities from perfect-match (PM) probes only, MEAP PM-BayesBG model
was built upon the exon array speciﬁc background probe pool and takes probe sequence
composition into account to achieve more accuracy in the background noise estimation. In
addition, MEAP uses its own probe annotation for each Ensembl release to avoid biases
from outdated annotations. The embedded parallelization makes MEAP as a time-efﬁcient
method to process hundreds of arrays at the same time, which is not the case for other
popular methods, such as RMA, GCRMA, PLIER and MAS5 [244, 245, 246].
As MEAP quantiﬁes expression data based on annotations, the annotation quality is
crucial for the quantiﬁcation accuracy, especially at the alternative splicing level. MEAP
annotation was built based on Ensembl release, in which transcript isoforms reported by
CCDS, UCSC, RefSeq or Havana/Ensembl merges are quantiﬁed. Such annotation-based
method is not able to discover and quantify novel events. Furthermore, the hybridization-
based measurements may not be able to detect target fragments when mutations occur at
the hybridization regions.
Cancer is a heterogeneous disease with multiple subtypes stratiﬁed by distinct molecular
proﬁles [1, 2, 3, 183]. In Publication IV, a novel computational approach, PSFinder,
was developed to stratify tumor samples into prognostic subgroups based on integrated
expression and clinical data. There are several other methods to identify prognostic
subgroups, such as CLOVAR [196] and SAPS [247], but PSFinder is unique as it assumes
that patients with similar prognosis under certain treatments may share similar co-expressed
transcriptional networks and survival association.
The application of PSFinder in HGS-OvCa revealed interesting subgroups (Poor I, Poor II
and Good) stratiﬁed by a small set of isoform-level and gene-level markers. In these
three subgroups, Poor II is a well-studied poor prognostic subgroup categorized by
stroma-related signatures, whereas Poor I, a novel subgroup, is associated with short
overall survival characterized by increased promoter hypermethylation. Combination with
BRCA1/2 mutation status provides an even better stratiﬁcation on the prognosis of patients
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treated with platinum-taxane combination therapy, which may facilitate the selection of
chemo-resistant HGS-OvCa patients for clinical trials. In addition, in vitro demethylation
experiments on Poor I characteristic cell lines further suggests the therapeutic potential of
demethylation drugs on Poor I characteristic HGS-OvCa patients.
PSFinder is a broad approach that can be applied to any clinically annotated cancer
transcriptome data. Beside the ovarian cancer, it has been applied to several other cancers,
such as breast cancer and glioblastoma (manuscript in preparation). Future work will focus
on interpreting the results from these analyses.
The dynamics of transcriptome is regulated by various factors, such as genetic variations,
epigenetic alteration and miRNA expression, which were not intensively explored in this
thesis. Systematic study using large amounts of high-throughput data from multiple layers
is a promising strategy to uncover such connections in order to decipher the regulatory
mechanisms, which will continue to be an interesting ﬁeld in the next few decades.
The complexity of omics and increasing amounts of omic data brings challenges to the
systematic study, which requires continuous improvement of both measurement technology
and computational innovations. For example, in terms of RNA-seq, when much longer
sequences can be read, the quantiﬁcation at splicing variant level will not be a challenging
task any more, and with the help of advanced computational methods, the quantiﬁcation
quality will be improved. From the biomedical perspective, understanding the mechanism
in transcriptomic regulation through theoretical research can help in the discovery of
disease-causing factors, especially in cancer.
The heterogeneity of cancer makes it a complicated disease with various subtypes respond-
ing differently to tumor therapies. Precision medicine is an emerging promising approach
to treat cancer in a personalized way based on the molecular classiﬁcation [248]. Due
to the improved efﬁciency and decreased cost of high-throughput technologies, a wealth
of cancer omics data is becoming available. Therefore, in the future, more efforts have
to be made to utilize these high-throughput data to gain better insights into the biological
mechanism of chemoresistance in cancer cells. Beyond cancer subtypes, the tumor itself is
comprised of subclones. Tumor microenvironment and inter-clonal cooperation may lead
to therapeutic resistance [249, 250]. However, these interactions are challenging to detect
and catalog. Therefore, advanced methodology to isolate and proﬁle each compartment of
the microenvironment and subclones is needed and may shed new light on the molecular
mechanism of drug resistance.
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